Page last updated: 2024-12-06

artesunate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917864
CHEMBL ID361497
CHEBI ID63918
SCHEMBL ID14552891
MeSH IDM0118766

Synonyms (86)

Synonym
nuartez
wr-256283
arinate
plasmotrim
arsumax
artsuna
(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate
artesunic acid
nsc-712571
quinghaosu reduced succinate ester
chebi:63918 ,
bdbm50248021
dtxsid3042681 ,
CHEMBL361497
ljpc-0118
.alpha.-artesunic acid
dihydroqinghaosu hemisuccinate
armax 200
butanedioic acid, mono((3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
saphnate
artesunate [usan:inn:ban]
arsuamoon
cosinate
asumax
unii-60w3249t9m
4-oxo-4-(((3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate
dihydroqinghasu hemsuccinate
artesunatum
plasmotrin
gsunate forte
artesunato
wr 256283
artesunata
artesunatum [inn-latin]
zysunate
60w3249t9m ,
dihydroartemisinine-12alpha-succinate
qinghaozhi
artesunato [inn-spanish]
hsdb 7458
4-oxo-4-{[(3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]oxy}butanoic acid
butanedioic acid, 1-[(3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester
4-oxo-4-(((3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid
artesunate [orange book]
3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate
artesunate [mi]
artesunate [mart.]
artesunate [hsdb]
artesunate [usp-rs]
4-oxo-4-(3r,5as,6r,8as,9r,10s,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate
artesunate [usan]
artesunate [who-dd]
artesunate [inn]
artesunatum [who-ip latin]
dihydroartemisinine-12.alpha.-succinate
butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester, (3r-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.beta.,12.beta.,12ar*))-
artesunate [vandf]
artesunate [who-ip]
MLS006011590
smr002499399
SCHEMBL14552891
cosunate
DB09274
4-oxo-4-[[(1r,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
CS-8151
FIHJKUPKCHIPAT-AHIGJZGOSA-N
HY-N0193
wr-256283;art;armax 200;sm-804;hsdb-7458
Q707939
gtpl9956
BRD-K54634444-001-05-9
d95 ,
4-oxo-4-{[(1r,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,(1)(3).0?,(1)(3)]hexadecan-10-yl]oxy}butanoic acid
STR09744
NCGC00164600-10
butanedioic acid, mono((5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
NCGC00164600-15
AKOS037515734
p01be03
artesunate (usp-rs)
artesunatum (inn-latin)
artesunate (mart.)
butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12ar*))-
artesunato (inn-spanish)
EN300-6482026
4-oxo-4-{[(1r,4s,5r,8s,9r,10s,12r,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-yl]oxy}butanoic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The resulting pharmacokinetic parameter estimates were substantially different not only between drugs but also between routes of administration for the same drug."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
"A single cross-over, comparative pharmacokinetic study of oral and rectal formulations of 200 mg artesunic acid in 12 healthy Malaysian volunteers is reported."( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers.
Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998
)
0.3
"Comparison of pharmacokinetic parameters of artesunic acid after oral and rectal administration showed statistically significant differences in t(max) and AUC, with no changes for Cmax and t1/2."( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers.
Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998
)
0.3
"There appear to be pharmacokinetic differences between oral and rectal modes of administration."( Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers.
Abdullah, MN; Akbar, A; Mansor, SM; Mordi, MN; Navaratnam, V, 1998
)
0.3
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic (PK) data informing the optimum dosing of these drug regimens is limited, especially in children."( Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Annerberg, A; Aweeka, F; Clark, TD; Dorsey, G; Drysdale, T; German, P; Kalyango, JN; Kamya, MR; Lindegardh, N; McGee, B; Mwesigwa, J; Parikh, S; Rosenthal, PJ, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Our data support the idea that ciprofloxacin in combination with antimalarials may be useful in the treatment of chloroquine-resistant human malaria, allowing the use of lower doses of these drugs."( Enhanced activity of mefloquine and artesunic acid against Plasmodium falciparum in vitro and P. berghei in mice by combination with ciprofloxacin.
Andrade, AA; Boechat, N; de Freitas, IO; de Pilla Varotti, F; de Souza, MV; Krettli, AU; Vasconcelos, TR, 2007
)
0.34
" The isobolar equivalent (IE) calculated from the ED90 of PCE in combination with artesunic acid showed that the interaction was antagonistic."( Antagonistic antimalarial properties of pawpaw leaf aqueous extract in combination with artesunic acid in Plasmodium berghei-infected mice.
Attama, AA; Esimone, CO; Ngene, AA; Okore, VC; Onaku, LO; Tijani, AY, 2011
)
0.37
"Although pawpaw alone was found to have a very good activity, its combination with artesunic acid is antagonistic."( Antagonistic antimalarial properties of pawpaw leaf aqueous extract in combination with artesunic acid in Plasmodium berghei-infected mice.
Attama, AA; Esimone, CO; Ngene, AA; Okore, VC; Onaku, LO; Tijani, AY, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetics and bioavailability of dihydroartemisinin (DQHS), artemether (AM), arteether (AE), artesunic acid (AS) and artelinic acid (AL) have been investigated in rats after single intravenous, intramuscular and intragastric doses of 10 mg kg(-1)."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
" Further pharmacokinetic studies showed that the bioavailability in rats following oral administration was 25 times greater for 11b than for artemether 1b."( Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
Bégué, JP; Bonnet-Delpon, D; Charman, WN; Charneau, S; Chorki, F; Crousse, B; Grellepois, F; Grellier, P; McIntosh, KA; Ourévitch, M; Pradines, B, 2004
)
0.32
" Pharmacokinetic studies in rats revealed good oral bioavailability (51% at 22 mg/kg) with a moderate rate of absorption, reasonable half-life (t(1/2) 3 h), and high volume of distribution with moderately high plasma and blood clearance after IV administration."( Novel orally active antimalarial thiazoles.
Burrows, JN; Charman, SA; Chibale, K; Douelle, F; Feng, TS; González Cabrera, D; Nchinda, AT; Ryan, E; Waterson, D; White, KL; Wittlin, S; Witty, MJ; Wu, Q; Younis, Y, 2011
)
0.37
" Furthermore, 35 displayed high (78%) rat oral bioavailability with good oral exposure and plasma half-life."( Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
Avery, VM; Charman, SA; Chibale, K; Douelle, F; Duffy, S; Gonzàlez Cabrera, D; Le Manach, C; March, C; Nchinda, AT; Ryan, E; Street, LJ; Taylor, D; Waterson, D; White, KL; Wiesner, L; Wittlin, S; Witty, MJ; Younis, Y, 2014
)
0.4
"Artesunic acid (ASH), an antimalarial drug, has low oral bioavailability due to its low aqueous solubility."( 2D Inorganic-Antimalarial Drug-Polymer Hybrid with pH-Responsive Solubility.
Choi, G; Choi, SJ; Choy, JH; Jo, MR; Kim, JY; Lee, JH; Park, DH; Yang, JH, 2015
)
0.42
"Tetrazole, a bioisostere of the carboxylic acid group, can replace the carboxyl group in drugs to increase the lipophilicity, bioavailability and reduce side effects."( Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents.
Chang, L; Ding, C; Feng, LS; Gao, C; Wu, X; Xu, Z; Yan, XF; Zhao, F, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Plasma was separated from blood samples collected at different times after dosing and analysed for parent drug."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
" falciparum malaria were randomly assigned to either one of the two dosing schemes."( Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria.
Jansen, FH; Penali, LK, 2008
)
0.35
" Pharmacokinetic (PK) data informing the optimum dosing of these drug regimens is limited, especially in children."( Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Annerberg, A; Aweeka, F; Clark, TD; Dorsey, G; Drysdale, T; German, P; Kalyango, JN; Kamya, MR; Lindegardh, N; McGee, B; Mwesigwa, J; Parikh, S; Rosenthal, PJ, 2010
)
0.36
" The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."( Spiroindolones, a potent compound class for the treatment of malaria.
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010
)
0.36
" The ED50 and ED90 were calculated from the dose-response relationships."( Antagonistic antimalarial properties of pawpaw leaf aqueous extract in combination with artesunic acid in Plasmodium berghei-infected mice.
Attama, AA; Esimone, CO; Ngene, AA; Okore, VC; Onaku, LO; Tijani, AY, 2011
)
0.37
" The ED50 was calculated from the dose-response relationships."( Azadirachta indica extract-artesunic acid combination produces an increased cure rate of Plasmodium berghei-infected mice.
Anagu, OL; Attama, AA; Esimone, CO; Gugu, HT; Ngene, AA; Okore, VC, 2014
)
0.4
" Furthermore, analogue 40 exhibited excellent in vivo antimalarial activity when dosed orally at 50 mg/kg once daily for 4 days in the Plasmodium berghei mouse model, which is superior to the activity seen with previously reported compounds, and with a slightly improved hERG profile."( Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
Chibale, K; Douelle, F; Gonzàlez Cabrera, D; Han, Z; Lawrence, N; Le Manach, C; Njoroge, M; Paquet, T; Street, LJ; Taylor, D; Waterson, D; Wiesner, L; Wittlin, S; Witty, MJ, 2015
)
0.42
" The observation of atypical dose-response curves when some compounds were tested against multidrug resistant malaria parasite strains guided the optimization process to define a chemical space that led to typical sigmoidal dose-response and complete kill of multidrug resistant parasites."( Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.
Basarab, GS; Brunschwig, C; Chibale, K; Duffy, J; Eyermann, CJ; Fish, PV; Gibhard, L; Lawrence, N; Le Manach, C; Nchinda, AT; Njoroge, M; Paquet, T; Street, LJ; Taylor, D; Wicht, K; Wittlin, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
ferroptosis inducerAny substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
artemisinin derivativeAny organic peroxide formally obtained from artemisinin.
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
hemisuccinateA succinate ester in which only one of the carboxy groups of succinic acid has been esterified.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency12.34630.009610.525035.4813AID1479145; AID1479148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (720)

Assay IDTitleYearJournalArticle
AID277701Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID1404600Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72018Journal of natural products, 04-27, Volume: 81, Issue:4
Microthecaline A, a Quinoline Serrulatane Alkaloid from the Roots of the Australian Desert Plant Eremophila microtheca.
AID1267693Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID563203Antiparasitic activity against Toxoplasma gondii RH infected in human foreskin fibroblasts monolayer after 72 hrs by bacterial beta-galactosidase reporter gene assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.
AID1327393Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID601748Antimalarial activity against Plasmodium berghei ANKA NK65 infected in po dosed Swiss Webster mouse assessed as reduction of parasitemia level administered qd for 4 days measured 24 hrs after last dose by light microscopic analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID1057253Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 10 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID445045Neurotoxicity in Sprague-Dawley rat at 300 mg/kg, po daily once for 5 days2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID445044Renal toxicity in Sprague-Dawley rat at 300 mg/kg, po daily once for 5 days2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID704020Antischistosomal activity against adult Schistosoma mansoni schistosomes incubated for 72 hrs in presence of 120 uM Fe(3)-hemin2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID636374Antimalarial activity against blood stage of Plasmodium berghei NK65 infected in iv dosed rat assessed as minimum curative dose2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID1472096Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum 7G8 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID395097Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID1197876Antimalarial activity against Plasmodium falciparum infected in SCID mouse engrafted with human erythrocytes assessed as reduction in parasitemia at 13 mg/kg, po qd for 4 days relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID636376Acute toxicity in iv dosed Sprague-Dawley rat assessed as maximum tolerated dose2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID1186055Antiinflammatory activity in mouse BV2 cells assessed as LPS/IFNgamma-induced COX2 expression at 4 uM after 24 hrs by Western blot2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1186059Toxicity against LPS/IFNgamma-induced mouse BV2 cells assessed as cell viability at 0.5 to 4 uM pre-incubated before LPS/IFNgamma challenge and measured 24 hrs post LPS/IFNgamma challenge by MTT assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID562277Antiparasitic activity against Schistosoma mansoni assessed as parasite death at 300 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID1661954Binding affinity to Ebola virus glycoprotein assessed as dissociation constant incubated for 20 to 30 mins by microscale thermophoresis2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID1714084Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs b2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID630862Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum K12011Journal of medicinal chemistry, Nov-10, Volume: 54, Issue:21
Novel orally active antimalarial thiazoles.
AID728699Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as survival at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1894308Inhibition of Beta-hematin assessed as bis-pyridyl-Fe(III)PPIX complex formation incubated for 5 hrs by NP40 detergent-mediated colorimetric assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1162946Antiplasmodial activity against Plasmodium falciparum 3D7 asexual blood stages after 3 days by HRP2 detection based ELISA method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1733341Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID1633696Resistance index, ratio of IC50 for antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 incubated for 48 hrs by parasite lactate dehydrogenase assay to IC50 for antiplasmodial activity against chloroquine-sensitive Plasmodium f2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID518336Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitemia at 100 mg/kg, perorally administered as single dose measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1751421Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal filamentation in YEPD containing 10% serum medium at 100 uM incubated for 1 hr by microscopic analysis2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID1239477Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID1227811Toxicity in BALB/c nude mouse assessed as animal death at 0.023 mmol/kg, ip administered every 2 days for 3 times measured on day 62015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID497992AUC (0-infinity) in Ugandan children patient with uncomplicated malaria at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID442258Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1077196Cytotoxicity against CHO cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1191134Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID673148Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 100 mg/kg, po administered 24 hrs post infection (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1267689Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1327395Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF542016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1433124Resistance index, ratio of IC50 for chloroquine-resistant asexual intraerythrocytic stage of Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive asexual intraerythrocytic stage of Plasmodium falciparum NF542015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1355303Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 24 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID1464214Phototoxicity against human HepG2 cells assessed as reduction in cell viability up to 100 uM irradiated with LED light at 1.7 J/cm'2 measured after 12 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 10-01, Volume: 27, Issue:19
Synergistic antiproliferative effect of chemo-phototherapy: Synthesis and photodynamic activity evaluation of novel Chlorin e6-artesunate conjugates as antiproliferative agents.
AID774661Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1515768Antimalarial activity against synchronized ring stage Plasmodium falciparum 3D7 transfected with nano-luciferase assessed as parasite growth inhibition after 48 hrs by Nano-Glo luciferase assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Repositioning Salirasib as a new antimalarial agent.
AID519195Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID1460342Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID658605Resistant factor, ratio of IC50 for chloroquine-resistant Plasmodium falciparum K1 to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1201059Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID285475Antimalarial activity against Plasmodium vinckei petteri infected orally dosed Swiss Albino mice (Mus musculus)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID1574648Growth inhibition of HEK293 cells at 10 uM after 72 hrs by resazurin dye based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1552379Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigerian infected in human blood after 48 hrs by [3H]-hypoxanthine incorporation assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.
AID1462235Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID1638539Antimalarial activity against multidrug-resistant Plasmodium vivax clinical isolates assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1563888Antiplasmodial activity against chloroquine-resistant asexual blood stage of Plasmodium falciparum K1 by LDH assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insights.
AID1462231Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based fluorescence microscopic analysis2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID1648004Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1380022Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine and pyrimethamine resistant Plasmodium falciparum K12017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.
AID755424Cytotoxicity against human SKHEP1 cells after 72 hrs in presence of hemin2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID285469Antimalarial activity against chloroquine-sensitive Plasmodium falciparum F322007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID661149Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID748937Antimalarial activity against Plasmodium falciparum infected in po dosed mouse assessed as decrease in parasitemia administered on day 1 postinfection measured on day 3 by FACS analysis2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1274587Cytotoxicity against HEK293 cells assessed as cell viability at 20 uM after 72 hrs by resazurin-based plate reader analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1204122Selectivity index, ratio of CC50 for human HeLa cells to IC50 for CQ-sensitive Plasmodium falciparum 3D72015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1524522Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
AID442266Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PA infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID768480Gametocytocidal activity against synchronous stage 4 to 5 of transgenic Plasmodium falciparum NF54 gametocyte harboring pfs16 promoter assessed as parasite viability after 72 hrs by MitoTracker Red CMXRos-based assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1771329Antimalarial activity against Plasmodium falciparum Dd2 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting met2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID285474Antimalarial activity against Plasmodium vinckei petteri infected intraperitoneally dosed Swiss Albino mice (Mus musculus)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID452986Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF542010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID285476Antimalarial activity against Plasmodium vinckei petteri infected subcutaneously dosed Swiss Albino mice (Mus musculus)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID443095Antimalarial activity against Plasmodium berghei ANKA infected Swiss CD1 mice (Mus musculus) assessed as reduction of parasitemia at 30 mg/kg, perorally administered after 3 hrs of infection for 3 days measured on day 4 relative to control2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1472097Cytotoxicity against CHO cells by MTT assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID518571Antimalarial activity against Plasmodium berghei ANKA infected in perorally dosed NMRI mice (Mus musculus) assessed as reduction in parasitemia administered as single dose measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444925Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human A+ erythrocytes assessed as [3H]hypoxanthine incorporation by semi-automated micro dilution assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID510919Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measure2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID576713Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID576728Antimalarial activity against Plasmodium falciparum D10 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1304201Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID576575Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1274589Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1204117Cytotoxic activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1498472Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green dye fluorescence assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID480167Antiparasitic activity against Fasciola hepatica infected in rat assessed as reduction in worm burden at 100 mg/kg, po administered as single dose measured after 6 days post treatment2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica.
AID1201061Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D72015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID1267722Inhibition of P-glycoprotein in human K562/ADR cells at 6.5 uM after 48 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1779233Antimalarial activity against synchronous ring stage of Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID520093Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID1433123Antimalarial activity against chloroquine-resistant asexual intraerythrocytic stage of Plasmodium falciparum Dd2 assessed as inhibition of parasite growth by lactate dehydrogenase assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1513845Antiplasmodial activity against Plasmodium falciparum NF54 after 48 hrs by lactate dehydrogenase assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.
AID1232060Cytotoxicity against human MRC5 cells2014MedChemComm, Jul-01, Volume: 5, Issue:7
The biology and synthesis of α-hydroxytropolones.
AID1128651Antimalarial activity against drug-sensitive Plasmodium falciparum NF542014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1232059Antimalarial activity against Plasmodium falciparum FCR-3/Gambia2014MedChemComm, Jul-01, Volume: 5, Issue:7
The biology and synthesis of α-hydroxytropolones.
AID1353871Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum NF542018European journal of medicinal chemistry, Mar-25, Volume: 148Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity.
AID510911Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1355625Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage parasites infected in human erythrocytes after 72 hrs by SYBR Green 1 dye based fluorescence assay
AID1327389Antiplasmodial activity against chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54 measured after 48 hrs by pLDH assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID576727Antimalarial activity against Plasmodium falciparum D10 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1070213Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive Plasmodium falciparum NF542014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.
AID1639289Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence assay relative to control2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID755430Cytotoxicity against human LS 174T cells after 72 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1355622Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
AID661147Drug degradation in aqueous NaHCO3 under ambient temperature within 48 hrs2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID1375180Antimalarial activity against drug-sensitive Plasmodium falciparum NF542018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ
AID1267713Induction of apoptosis in human K562/ADR cells assessed as induction of cell shrinkage at 6.5 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1573776Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in type A-positive human erythrocytes after 72 hrs by SYBR green 1 dye-based fluorescence assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID518534Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitemia at 3 times 30 mg/kg, perorally measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1351442Induction of apoptosis in tumor of colorectal cancer patient at 200 mg/day, po administered for 14 days relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Natural compounds and combination therapy in colorectal cancer treatment.
AID774658Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1304203Antimalarial activity against multidrug resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID520094Induction of heme alkylation of Fe(II) heme assessed as adduct A472 absorbance change at completion of reaction at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID529759Antimicrobial activity against Plasmodium falciparum at ring stage2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1421917Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 late stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID453152Metabolic stability in human liver microsomes assessed as hepatic extraction ratio2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID1633697Selectivity index, ratio of IC50 for CHO cells to IC50 for antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID1751420Potentiation of fluconazole-induced antifungal activity against Candida albicans SC5314 assessed as fungal growth at 100 microM measured after 24 hrs in presence of fluconazole by absorbance based analysis relative to fluconazole-treated control2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID586610Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID510910Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID755427Acute toxicity in human HepG2 cells at IC50 after 6 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID444924Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human A+ erythrocytes assessed as [3H]hypoxanthine incorporation by semiautomated micro dilution assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID585009Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID682362Cytotoxicity against human CCRF-CEM cells by CCK-8 assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells.
AID1163786Antimalarial activity against Plasmodium berghei ANKA infected in CD1 Swiss albino mouse assessed as reduction in parasitemia2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents.
AID576724Antimalarial activity against Plasmodium falciparum D10 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID252957Ratio of concentration that reduced cell viability to inhibitory concentration for ConA-induced T cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID576723Antimalarial activity against Plasmodium falciparum D10 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1648007Cytotoxicity against HEK293 cells assessed as growth inhibition at 20 uM relative to control2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID519198Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID568770Cytotoxicity against human HEK293 cells after 72 hrs by alamar blue assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Phenolic glycosides with antimalarial activity from Grevillea "Poorinda Queen".
AID1304205Resistance index, ratio of IC50 for multi-drug-resistant Plasmodium falciparum W2 infected in human erythrocytes to IC50 for chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID1304207Selectivity index, ratio of IC50 for human WI38 cells to IC50 chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID1197872Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po qd for 4 days starting 4 hrs post infection measured on 96 hrs post infection relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID443096Antimalarial activity against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) assessed as reduction of parasitemia treated perorally for 3 days measured on day 42010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1648003Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1204118Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1733342Cytotoxicity in human J82 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID648237Antimalarial activity against Plasmodium falciparum 3D7 0087/N9 infected in human RBC engrafted NOD-SCID IL-2Rgamma-null mouse assessed as reduction in parasitemia administered orally 3 days post infection qd for 4 days measured 24 hrs after final dose by2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.
AID1169323Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 asexual erythrocyte stages by parasite lactate dehydrogenase assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Structure-activity relationship studies of antiplasmodial aminomethylthiazoles.
AID510940Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia dosed in ETPGS formulation 1 day post infection measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID586606Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1057254Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 3 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1688333Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 by SyBR Green method2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID1655970Inhibition of human TOP1B-medaited negatively supercoiled pBlue-Script KSII(+) DNA relaxation at 0.3 to 30 uM by ethidium bromide staining based gel electrophoresis method2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1.
AID728702Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1504883Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based confocal microplate imaging method2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID731504Gametocytocidal antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 late gametocyte stage after 72 hrs by alamar blue assay2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Antiproliferative and antiplasmodial dimeric phloroglucinols from Mallotus oppositifolius from the Madagascar Dry Forest (1).
AID276160Antimalarial activity in Plasmodium berghei infected MORO mice (Mus musculus) at 10 mg/kg peroral dose2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID442262Therapeutic index, ratio of IC50 for concanavalin-stimulated BALB/c mice (Mus musculus) splenocytes to IC50 for Plasmodium falciparum W2 after 48 hrs2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1587111Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation pretreated for 24 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by 2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID1858896Antimalarial activity against drug resistant Plasmodium falciparum K12021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1612608Antimalarial activity against ring-stage multidrug-resistant Plasmodium falciparum Dd2 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents.
AID755426Acute toxicity in human LS 174T cells at IC50 after 6 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID519197Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID543632Antimicrobial activity against Echinococcus multilocularis -infected in BALB/c mouse assessed as parasite weight at 200 mg/kg body weight intragastrically administered 8 weeks post-infecion (Rvb = 5.71+/-1.79 g)2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID576729Antimalarial activity against Plasmodium falciparum D10 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1204120Antimalarial activity against CQ-resistant Plasmodium falciparum W2 cultivated in human type O+ red blood cells assessed as reduction in parasite infection incubated for 48 hrs by microscopy2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1057250Cytotoxicity against human HT29-AK cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID510922Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured 96 hrs post inf2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1423844Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID565416Antimalarial activity against Plasmodium falciparum PfV1S0176/N10 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1638537Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID444927Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction of parasitaemia level at 3 mg/kg, perorally daily once for 3 consecutive days measured after 4 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID1431588Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP early stage 1 to 3 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID248433In vitro concentration of compound required to inhibit LPS-induced B cell proliferation to 50% in BALB/c mice2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1201065Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SRIV352015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID442256Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID251469Antimalarial activity (10 mg/kg, peroral) given 1 day post infection of mice (Mus musculus) with Plasmodium berghei is its ability to reduce parasitaemia on day 3 post infection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1327392Cytotoxicity against human WI38 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID158373In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Antimalarial activities of (+)-deoxoartemisitene and its novel C-11, 13 derivatives.
AID117697Percentage reduction of parasitaemia at day 4 at a concentration of 10 mg/kg by subcutaneous administration2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
AID576577Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1057251Antimalarial activity against Plasmodium berghei ANKA infected in po dosed mouse assessed as inhibition of parasitemia administered for 3 days post-infection measured on day 4 by Giemsa staining2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1247011Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID636372Antimalarial activity against blood stage of Plasmodium berghei NK65 infected in iv dosed rat assessed as inhibition of parasite growth2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID112572In vivo effective dose was evaluated against Plasmodium berghei N by peroral administration in mice (Mus musculus)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
AID1375185Antimalarial activity against multidrug-resistant Plasmodium falciparum K12018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1267690Antiproliferative activity against human K562/ADR cells assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1714098Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse model assessed as reduction in parasitemia at 30 mg/kg, po qd for 4 consecutive days measured at day 7 post infection by flow cytometry analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID1546475Cytotoxicity against human MG63 cells assessed as cell viability after 48 hrs in presence of allicin by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1128650Antimalarial activity against multidrug-resistant Plasmodium falciparum K12014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID510925Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured on day 30 post2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID285471Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB12007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID1462233Selectivity ratio of IC50 for Plasmodium falciparum Dd2 to IC50 for Plasmodium falciparum 3D72017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID1277744Antiparasitic activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
AID1541856Antimalarial activity against Plasmodium falciparum TM90C2B incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID1858895Antimalarial activity against drug sensitive Plasmodium falciparum NF542021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID511100Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 96 hrs post infecti2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1128658Antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as reduction of parasitemia at 30 mg/kg, po qd for 4 days2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1699387Antileishmanial activity against Leishmania donovani amastigotes infected in human THP1 cells assessed as reduction in parasite infection measured after 72 hrs by Giemsa staining-based assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID673143Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 30 mg/kg, po administered 24 hrs post infection measured after 72 hrs post infection by flow cytometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1235981Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition by parasite lactate dehydrogenase assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine.
AID113354In vivo effective dose evaluated against Plasmodium berghei N by peroral administration in mice (Mus musculus)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
AID1232061Antimalarial activity against Plasmodium falciparum infected in mouse2014MedChemComm, Jul-01, Volume: 5, Issue:7
The biology and synthesis of α-hydroxytropolones.
AID1327390Antiplasmodial activity against chloroquine-resistant asexual erythrocyte stage form Plasmodium falciparum Dd2 measured after 48 hrs by pLDH assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID248451In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1505094Antiplasmodial activity against drug-sensitive blood stage Plasmodium falciparum 3D7 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID1858897Antimalarial activity against drug resistant Plasmodium falciparum W22021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1355873Cytotoxicity against human HEK293 cells at 40 uM after 72 hrs by resazurin dye based fluorescence assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID1472088Resistance index, ratio of IC50 for chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID755421Cytotoxicity against human SKHEP1 cells incubated for 1 hr prior to ferrosanol addition measured after 72 hrs2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1546493Antitumour activity against human CFPAC-1 cells xenografted in ip dosed nude BALB/c mouse assessed as tumor weight for 18 days2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID661143Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as disease cured mouse at 12 mg/kg, im administered once daily for 4 days measured on day2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID1267691Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID251231Survival of mice to 30-day postinfection with Plasmodium berghei upon 10 mg/kg peroral dose was determined2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1076689Antimalarial activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 3 days by HRP2 based ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum and multidrug-resistant human leukemia cells.
AID279860Antimalarial activity against Plasmodium falciparum NF54 within 48 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).
AID1750030Antiplasmodial activity against Plasmodium berghei ANKA infected in po dosed Swiss mouse administered at 2 hrs post infection and measured on day 4 by Peter's 4-day test
AID1186061Inhibition of NFkappaB (unknown origin) expressed in HEK293 cells assessed as TNFalpha-induced gene transcription at 4 uM pre-incubated for 30 mins prior to stimulation with TNFalpha for 6 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1077199Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1445954Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as parasite-free mouse at 30 mg/kg, po administered at 4, 24, 48, 72 hrs post infection measured on day 30 by Peter's test2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1254177Antiplasmodial activity against multidrug resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID565415Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-beta2 m null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1076688Cytotoxicity against human CCRF-CEM cells by resazurin assay2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum and multidrug-resistant human leukemia cells.
AID1541854Antimalarial activity against Plasmodium falciparum NF54 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID1706808Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 infected in erythrocytes by SYBR Green dye based fluorescence assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
AID317969Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
AID1616630Antiplasmodial activity against asexual form of Plasmodium falciparum NF54 assessed as reduction in female gametocytes activation preincubated for 48 hrs followed by gametocytes activation and measured after 24 hrs by fluorescence based automated inverted2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID682363Cytotoxicity against human CEM/ADR5000 by CCK-8 assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells.
AID277702Antimalarial activity against Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose over 4 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID1239480Resistance index, ratio of IC50 for human CEM/ADR5000 cells to IC50 for human CCRF-CEM cells2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID442257Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1423840Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in HFF measured 7 days post infection2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID247005Effective dose required to reduce the parasitemia in mice when compound administered with SSV after 3 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID442268Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCM29 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID555962Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
AID1464212Dark toxicity against human HepG2 cells assessed as reduction in cell viability incubated overnight by MTT assay2017Bioorganic & medicinal chemistry letters, 10-01, Volume: 27, Issue:19
Synergistic antiproliferative effect of chemo-phototherapy: Synthesis and photodynamic activity evaluation of novel Chlorin e6-artesunate conjugates as antiproliferative agents.
AID518542Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as survival rate at 3 times 30 mg/kg, perorally2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID285480Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 4 & 5)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID520092Induction of heme alkylation of Fe(II) heme assessed as loss of heme at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
AID755425Cytotoxicity against human SKHEP1 cells after 72 hrs in presence of ferrosanol2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID519196Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID1639283Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1529414Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by li2018MedChemComm, Oct-01, Volume: 9, Issue:10
Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.
AID568772Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Phenolic glycosides with antimalarial activity from Grevillea "Poorinda Queen".
AID1247014Selectivity index, ratio of EC50 for human HepG2A16 cells to EC50 for chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID247016Effective dose required to reduce the parasitemia in mice when compound administered with Tween-80 after 3 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1267701Induction of apoptosis in human K562/ADR cells assessed as viable cells at 6.5 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 93.25%)2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID759418Selectivity index, ratio of IC50 for human MCF10A cells to IC50 for human MDA-MB-231 cells2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
AID1445952Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po administered at 4, 24, 48, 72 hrs post infection measured on day 4 by Peter's test relative to control2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1633692Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 incubated for 48 hrs by parasite lactate dehydrogenase assay2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID1545511Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green1 dye based fluorescence assay relative to control2019European journal of medicinal chemistry, May-15, Volume: 170Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
AID1545831Antiproliferative activity against human HepG2 cells by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID491640Increase in ROS generation in human CEM/ADR5000 cells at at 0 01 ug/ml after 72 hrs using 2',7'-dichlorodihydrofluoresceine diacetate staining by flow cytometry2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID1524520Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
AID252956Ratio of concentration that reduced cell viability to inhibitory concentration for LPS-induced B cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1227806Toxicity in mouse assessed as body weight loss at 0.43 mmol, ip2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1733343Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID1723644Antileishmanial activity against Leishmania donovani promastigotes2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Expanding the scope of synthetic 1,2,4-trioxanes towards Trypanosoma cruzi and Leishmania donovani.
AID1638538Antimalarial activity against multidrug-resistant Plasmodium falciparum clinical isolates infected assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1445943Antispasmodial activity against multidrug-resistant asexual blood stages of Plasmodium falciparum Dd2 after 72 hrs by HRP2-based ELISA2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1571713Antiplasmodium activity against chloroquine-sensitive Plasmodium falciparum NF54 asexual blood stage forms infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method2019MedChemComm, Mar-01, Volume: 10, Issue:3
Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles.
AID1186071Inhibition of LPS/IFNgamma-induced p38 phosphorylation in mouse BV2 cells at 1 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1733340Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID1175720Antigametocytocidal activity against Plasmodium falciparum NF54-pfs16-GPF early (1 to 3) gametocyte assessed as viability after 72 hrs by MitoTracker Red CM-H2XRos/micro-plate confocal imaging system2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
AID523425Antiplasmodial activity against artemisinin-tolerant Plasmodium falciparum F32-Tanzania assessed as time required to reach 5% parasitaemia at 2.6 uM treated for 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.
AID1433122Antimalarial activity against chloroquine-sensitive asexual intraerythrocytic stage of Plasmodium falciparum NF54 assessed as inhibition of parasite growth by lactate dehydrogenase assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID246938Effective dose required to reduce the parasitemia in mice by suppressive test after 4 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID543628Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 10 uM by trypan blue exclusion assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID576719Antimalarial activity against Plasmodium falciparum 7G8 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1609531Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1423848Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID523424Antiplasmodial activity against Plasmodium falciparum F32-Tanzania assessed as time required to reach 5% parasitaemia at 2.6 uM treated for 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.
AID277704Antimalarial activity against Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 24 mg/kg peroral dose over 4 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID1464213Phototoxicity against human HepG2 cells assessed as reduction in cell viability preincubated overnight followed by irradiation with LED light at 1.7 J/cm'2 for 10 mins measured post overnight incubation by MTT assay2017Bioorganic & medicinal chemistry letters, 10-01, Volume: 27, Issue:19
Synergistic antiproliferative effect of chemo-phototherapy: Synthesis and photodynamic activity evaluation of novel Chlorin e6-artesunate conjugates as antiproliferative agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID704021Cytotoxicity against rat L6 cells incubated for 690 hrs by Alamar blue assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1504889Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID755429Cytotoxicity against human SKHEP1 cells after 72 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1421916Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1267698Cell cycle arrest in human K562/ADR cells assessed as accumulation in G2/M phase at 6.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 8.32 +/- 0.81%)2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1254216Antiplasmodial activity against Plasmodium falciparum 3D7 infected in po dosed non-myelodepleted NOD-SCID IL2Rgammanull mouse engrafted with human erythrocytes assessed as reduction of parasitemia level administered qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID395100Resistance factor, ratio of IC50 for TbAT1 knock out Trypanosoma brucei brucei mutant to IC50 for wild type Trypanosoma brucei brucei s4272009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID286666Survival of Plasmodium berghei GFP infected mice (Mus musculus) at 10 mg/kg, subcutaneous after single dose2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Malaria-infected mice are cured by a single dose of novel artemisinin derivatives.
AID1186053Antiinflammatory activity in mouse BV2 cells assessed as LPS/IFNgamma-induced PGE2 production at 4 uM after 24 hrs by enzyme immunoassay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1423850Antiproliferative activity against human C33A cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID276159Antimalarial activity against Plasmodium falciparum NF542006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID1186052Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS/IFNgamma-induced PGE2 production at 2 uM after 24 hrs by enzyme immunoassay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1574646Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1541835Antimalarial activity against asexual stage of Plasmodium falciparum K1 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay
AID518550Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 3 times 30 mg/kg, perorally measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID543630Antimicrobial activity against Echinococcus multilocularis metacestode assessed as increase in alkaline phosphatase activity at 10 uM2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1304202Antimalarial activity against multidrug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID518558Toxicity in NMRI mice (Mus musculus) infected with Plasmodium berghei ANKA at 3 times 30 mg/kg, perorally measured up to 30 days postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1267695Resistance factor, ratio of IC50 for human K562/ADR cells to IC50 for human K562 cells2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1404595Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based fluorescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microthecaline A, a Quinoline Serrulatane Alkaloid from the Roots of the Australian Desert Plant Eremophila microtheca.
AID1496853Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in humanized NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mouse assessed as reduction in parasitemia administered 4 daily doses by SYTO-16 dye-based flow cytometric analysis2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID704024Cytotoxicity against human MRC5 cells incubated for 48 hrs by resazurin dye reduction assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID543633Toxicity against Echinococcus multilocularis -infected in BALB/c mouse assessed as adverse effect2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1546472Cytotoxicity against human HGC27 assessed as cell viability at 160 mg/l after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1445942Antispasmodial activity against chloroquine-sensitive asexual blood stages of Plasmodium falciparum 3D7 after 72 hrs by HRP2-based ELISA2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID285479Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 2 & 3)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID158372In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Antimalarial activities of (+)-deoxoartemisitene and its novel C-11, 13 derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1072530Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion after 21 days2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID482594Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered once daily for 3 days2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID1647632Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 incubated for 72 hrs by DAPI-staining based imaging analysis2020Journal of natural products, 02-28, Volume: 83, Issue:2
Orthoscuticellines A-E, β-Carboline Alkaloids from the Bryozoan
AID1380020Antiplasmodial activity against chloroquine sensitive Plasmodium falciparum NF54 assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.
AID704023Cytotoxicity against human HeLa cells incubated for 48 hrs by resazurin dye reduction assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1232058Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12014MedChemComm, Jul-01, Volume: 5, Issue:7
The biology and synthesis of α-hydroxytropolones.
AID1723647Antitrypanosomal activity against Trypanosoma cruzi epimastigotes2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Expanding the scope of synthetic 1,2,4-trioxanes towards Trypanosoma cruzi and Leishmania donovani.
AID1067864Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition by lactate dehydrogenase assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1267692Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID443098Antimalarial activity against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) assessed as mean survival time at 10 mg/kg, perorally 4 consecutive doses for 3 days measured on day 4 by FACS analysis2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1254196Antiplasmodial activity against Plasmodium berghei ANKA expressing GFP infected in mouse assessed as means survival days at 30 mg/kg, po qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID563202Cytotoxicity against HFF2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.
AID482593Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as host survival time at 100 mg/kg, perorally administered as single dose (Rvb = 6 to 7 days)2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID586607Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID605905Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as mouse survival at 30 mg/kg, po QD administered 24 hrs post infection for 3 days measured on day 30 post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID442269Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT K2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID661142Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as disease cured mouse at 24 mg/kg, im administered once daily for 4 days measured on day2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID1281535Antischistosomal activity against juvenile stage of Schistosoma japonicum infected in ICR mouse assessed as reduction of parasite burden at 400 mg/kg, po administered as single dose measured after 14 days2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID759417Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
AID1751423Potentiation of fluconazole-induced antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal filamentation by measuring reduction in fungal hyphae growth in YEPD containing 10% serum medium at 100 uM incubated for 1 hr in prese2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID1247013Cytotoxicity against human HepG2A16 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1355869Antiplasmodial activity against 4-aminoquinoline/antifolates-resistant Plasmodium falciparum Dd2 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID576725Antimalarial activity against Plasmodium falciparum D10 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1267725Inhibition of tubulin polymerization in human K562/ADR cells assessed as reduction in microtubule density at 13 uM after 16 hrs by DAPI staining based immunofluorescence microscopy2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1609530Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
AID1204119Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 cultivated in human type O+ red blood cells assessed as reduction in parasite infection incubated for 48 hrs by microscopy2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID586611Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1162948Gametocytocidal activity against transgenic Plasmodium falciparum NF54-pfs16-GFP late stage gametocytes after 72 hrs by mitotracker red CM-H2XRos dye based confocal imaging assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID321289Partition coefficient, log P of the compound2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID482597Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as host survival time at 30 mg/kg, perorally administered once daily for 3 days (Rvb = 6 to 7 days)2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID482595Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as host survival time at 10 mg/kg, perorally administered once daily for 3 days (Rvb = 6 to 7 days)2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID1450026Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 measured after 72 hrs by DAPI staining based high throughput screening assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID1541836Antimalarial activity against asexual stage of Plasmodium falciparum W2 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID285470Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigeria2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID1197873Antimalarial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival time at 30 mg/kg, po qd for 4 days starting 4 hrs post infection measured on 96 hrs post infection (Rvb = 4 days)2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID661136Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as suppression of parasitemia at 48 mg/kg, im administered once daily for 4 days relative2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID759420Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
AID1423849Antiproliferative activity against human SiHa cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID1186058Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS/IFNgamma-induced TNFalpha production at 1 to 4 uM pre-incubated before LPS/IFNgamma challenge and measured 24 hrs post LPS/IFNgamma challenge by ELISA method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID586612Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1574995Antiplasmodial activity against chloroquine-resistant asexual blood stage of Plasmodium falciparum K1 infected in human RBC assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured afte2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.
AID1437503Growth inhibition of HEK293 cells at 20 uM after 72 hrs by PrestoBlue staining based fluorescence assay relative to control
AID511099Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 962010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID442265Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTL1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID491634Cytotoxicity against human CEM/ADR5000 by XTT assay2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID576717Antimalarial activity against Plasmodium falciparum 7G8 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1699385Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by microplate alamar blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID251255Survival of mice to 30-day postinfection with Plasmodium berghei upon 10 mg/kg upon subcutaneous dose was determined2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1057255Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 1 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1239481Antiviral activity against Human cytomegalovirus AD169 expressing GFP infected in HFF assessed as inhibition of viral replication after 7 days2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID529758Antimicrobial activity against Plasmodium vivax at trophozoite stage2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID1355868Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID445042Liver toxicity in Sprague-Dawley rat at 300 mg/kg, po daily once for 5 days2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID1327387Thermal stability of the compound assessed as onset of decomposition temperature by thermogravimetric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID518549Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 100 mg/kg, perorally administered as single dose measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID661137Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as suppression of parasitemia at 24 mg/kg, im administered once daily for 4 days relative2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID630861Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum NF542011Journal of medicinal chemistry, Nov-10, Volume: 54, Issue:21
Novel orally active antimalarial thiazoles.
AID605815Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 100 mg/kg, po administered as single dose 24 hrs post infection measured 72 hrs post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID1380021Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.
AID1355623Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblast assessed as reduction in virus-induced cytopathic effect after 7 days
AID1751419Potentiation of micafungin-induced antifungal activity against Candida albicans SC5314 assessed as fungal growth at 100 microM measured after 24 hrs in presence of micafungin by absorbance based analysis relative to micafungin-treated control2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID452985Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1546525Cytotoxicity against human lymphocytes2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1771331Antimalarial activity against Plasmodium falciparum 7G8 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting met2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID576726Antimalarial activity against Plasmodium falciparum D10 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1057252Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 30 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1771330Antimalarial activity against Plasmodium falciparum K1 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting meth2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID1404601Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-resistant Plasmodium falciparum Dd22018Journal of natural products, 04-27, Volume: 81, Issue:4
Microthecaline A, a Quinoline Serrulatane Alkaloid from the Roots of the Australian Desert Plant Eremophila microtheca.
AID1227810Toxicity in BALB/c nude mouse assessed as body weight at 0.023 mmol/kg, ip administered every 2 days for 3 times measured on day 6 (Rvb = 17.5 to 17.9 gms)2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID1498471Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID452990Antimalarial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as cure rat at 3 mg/kg, perorally administered for 3 days post infection measured after 30 days2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID1267728Inhibition of tubulin polymerization in human K562/ADR cells assessed as microtubule disruption at 13 uM after 16 hrs by DAPI staining based immunofluorescence microscopy2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID482590Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered as single dose2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID497989Half life in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisinin level at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID543637Antimicrobial activity against Echinococcus granulosus metacestode assessed as loss of multicellular structure of germinal layer by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1612609Antimalarial activity against ring-stage chloroquine-susceptible Plasmodium falciparum 3D7 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Recent advances of tetrazole derivatives as potential anti-tubercular and anti-malarial agents.
AID704018Antischistosomal activity against Schistosoma mansoni NTS incubated for 72 hrs2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1546474Induction of cell death in human Y79 cells by propidium iodide staining based flow cytometric analysis relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID511098Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 96 hrs post infecti2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1541855Antimalarial activity against Plasmodium falciparum K1 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID1496712Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction in parasitemia at 30 mg/kg, po administered as single dose measured on day 3 relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID1524519Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
AID1574645Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1239475Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID1513846Antiplasmodial activity against Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.
AID1067865Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum D10 assessed as parasite growth inhibition by lactate dehydrogenase assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID1462237Cytotoxicity against HEK293 cells assessed as cell growth inhibition at 20 uM after 72 hrs by Alamar blue assay relative to control2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID1404593Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based fluorescence assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microthecaline A, a Quinoline Serrulatane Alkaloid from the Roots of the Australian Desert Plant Eremophila microtheca.
AID576711Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1546477Antitumour activity against human MG63 cells xenografted in nude BALB/c mouse assessed as tumour weight at 75 uM, ip for 5 days co-treated with allicin2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID442263Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTVo1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1450034Growth inhibition of HEK293 cells at 20 uM relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID1191138Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID1186069Inhibition of LPS/IFNgamma-induced IKKalpha phosphorylation in mouse BV2 cells at 1 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID510912Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered as single dose as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1633693Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 incubated for 48 hrs by parasite lactate dehydrogenase assay2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID395098Antitrypanosomal activity against TbAT1 knock out Trypanosoma brucei brucei mutant after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID1472094Antiplasmodial activity against chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF54 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID247107Effective dose required to reduce the parasitemia in mice by suppressive test after 4 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID452988Antimalarial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 3 mg/kg, perorally administered for 3 days post infection2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID1160942Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 6 post exposure relative to control2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID1327394Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF542016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID285481Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 asexual gametocytes2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID442259Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID276162Survival of MORO mice (Mus musculus) infected with Plasmodium berghei at 10 mg/kg, perorally after 30 day post-infection2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID518557Toxicity in NMRI mice (Mus musculus) infected with Plasmodium berghei ANKA at 100 mg/kg, perorally administered as single dose measured up to 30 days postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1267716Induction of apoptosis in human K562/ADR cells assessed as nuclear fragmentation at 6.5 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1732474Antimalarial activity against Plasmodium falciparum NF54 late stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1916295Invivo antimalarial activity against Plasmodium berghei ANKA strain infected in C57BL/6 mouse assessed as increase in mean survival time at 30 mg/kg, ip administered for 4 days and measured upto 30 days (Rvb = 13 days)
AID439586Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth after 48 hrs by [3H]hypoxanthine reuptake assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.
AID1267707Induction of apoptosis in human K562/ADR cells assessed as late apoptotic cells at 6.5 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 1.69%)2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID321287Antimalarial activity as reduced parasitemia day 4 against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 24 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID673145Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 30 mg/kg, po administered 24 hrs post infection qd for 3 days measured after 96 hrs post infection by flow cyto2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1196105Resistance index, ratio of IC50 for chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF542015European journal of medicinal chemistry, Mar-06, Volume: 92Synthesis of functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines and evaluation of their antiplasmodial and antifungal activity.
AID1186062Inhibition of IKK in mouse BV2 cells assessed as LPS/IFNgamma-induced IkappaB phosphorylation level at 0.5 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID276158Antimalarial activity against Plasmodium falciparum K12006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID1191135Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID1546473Cytotoxicity against human MGC803 assessed as cell viability at 160 mg/l after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID523300Antiplasmodial activity against artemisinin-tolerant Plasmodium falciparum F32-Tanzania assessed as time required to reach 5% parasitaemia at 9 uM treated for 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.
AID1274588Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1771328Antimalarial activity against Plasmodium falciparum NF54 assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID1196101Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF54 assessed as [3H]-hypoxanthine incorporation by lactate dehydrogenase assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Synthesis of functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines and evaluation of their antiplasmodial and antifungal activity.
AID563386Partition coefficient, log P of the compound at pH 22009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.
AID1445971Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 ring stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1427694Antiplasmodial activity against Plasmodium berghei ANKA harboring GFP-luc infected in CD-1 mouse assessed as reduction in parasitemia at 66.6 mg/kg, po administered immediately and at 24 and 48 hrs post infection measured up to 30 days post last dose by l2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit
AID1186072Inhibition of p38 in mouse BV2 cells assessed as reduction in LPS/IFNgamma-induced MAPKAPK2 phosphorylation at 1 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1204121Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for CQ-sensitive Plasmodium falciparum 3D72015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1057261Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite growth inhibition after 48 hrs by SYBR green-1 dye-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1247015Selectivity index, ratio of EC50 for human HepG2A16 cells to EC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1355621Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
AID658604Antiplasmodial activity chloroquine-resistant Plasmodium falciparum K1 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 24 hrs by scintillation counting2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1460343Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID1431589Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP late stage 4 to 5 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID762425Antimalarial activity against chloroquine-resistant Plasmodium falciparum 3D72013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Antimalarial and cytotoxic activities of chiral triamines.
AID510913Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1247012Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID482596Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered once daily for 3 days2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID1513842Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes preincubated for 48 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by liquid scintillation counting2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.
AID1639284Antiplasmodial activity against drug-resistant Plasmodium falciparum Dd2 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1431582Antimalarial activity against chloroquine and mefloquine resistant Plasmodium falciparum W2mef infected in human erythrocytes incubated for 72 hrs by LDH assay2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID1505184Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by lactate dehydrogenase assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Synthesis and Bioactivity of Reduced Chalcones Containing Sulfonamide Side Chains.
AID1267710Induction of apoptosis in human K562/ADR cells assessed as necrotic cells at 6.5 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 3.57%)2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID395099Antitrypanosomal activity against TbAT1 knock out and pentamidine-resistant Trypanosoma brucei brucei B48 mutant after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID704019Antischistosomal activity against adult Schistosoma mansoni schistosomes incubated for 72 hrs2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1505096Antiplasmodial activity against chloroquine/cycloguanil/pyrimethamine-resistant blood stage Plasmodium falciparum K1 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID497990AUC (0-infinity) in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisinin level at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on thi2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID585012Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID576722Antimalarial activity against Plasmodium falciparum 7G8 clone M4 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1186054Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS/IFNgamma-induced COX2 expression at 0.5 to 4 uM after 24 hrs by Western blot2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1186056Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS/IFNgamma-induced mPGES1 expression at 0.5 to 4 uM after 24 hrs by Western blot2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1541838Antimalarial activity against Plasmodium falciparum NF54 late gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay
AID1472099Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID1749956Bactericidal activity against Plasmodium falciparum 3D7A at 10 times IC50
AID444929Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as curing of parasitaemia at 3 mg/kg, perorally daily once for 3 consecutive days measured after 30 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID704425Antimicrobial activity against Plasmodium falciparum NF542011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
3-Alkoxy-1,2-Dioxolanes: Synthesis and Evaluation as Potential Antimalarial Agents.
AID774663Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1699384Antileishmanial activity against Leishmania donovani MHOM/NP/O2/BPK282/0cl4 promastigote assessed as reduction of growth inhibition incubated for 72 hrs by microplate alamar blue assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID704022Selectivity index, ratio of IC50 for rat L6 cells to IC50 for adult Schistosoma mansoni schistosomes2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1186064Inhibition of IKK in mouse BV2 cells assessed as LPS/IFNgamma-induced IkappaB phosphorylation level at 2 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID748938Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1574994Antiplasmodial activity against chloroquine-sensitive asexual blood stage of Plasmodium falciparum NF54 infected in human RBC assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured af2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.
AID772517Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID768481Gametocytocidal activity against synchronous stage 1 to 3 of transgenic Plasmodium falciparum NF54 gametocyte harboring pfs16 promoter assessed as parasite viability after 72 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.
AID1415895Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation cou2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID568771Selectivity index, ratio of IC50 for human HEK293 cells to IC50 for chloroquine, pyrimethamine, and mefloquine-resistant Plasmodium falciparum Dd22011Journal of natural products, Jan-28, Volume: 74, Issue:1
Phenolic glycosides with antimalarial activity from Grevillea "Poorinda Queen".
AID565414Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1706809Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
AID586608Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID661148Drug degradation in aqueous Na2CO3 under ambient temperature within 48 hrs2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID1070211Antiplasmodial activity chloroquine-sensitive Plasmodium falciparum NF54 by lactate dehydrogenase assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.
AID518541Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as survival rate at 100 mg/kg, perorally administered as single dose2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID417432Inhibition of beta-hematin formation at drug to heme molar equivalent ratio of 15 by infrared spectra measured after 18 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine.
AID1504881Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based confocal microplate imaging method2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID112574In vivo effective dose evaluated against Plasmodium berghei N by subcutaneous administration in mice (Mus musculus)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
AID1445972Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID277706Survival of Swiss mice (Mus musculus) infected with Plasmodium yoelii nigeriensis at 48 mg/kg, peroral after 28 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1546491Cytotoxicity against human CFPAC-1 cells assessed as cell viability after 24 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID245962In vitro concentration of compound required to reduced spleen cell viability to 50% in BALB/c mice2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1355304Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 48 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID248452In vitro inhibition of chloroquine-sensitive Plasmodium falciparum NF542005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1196102Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as [3H]-hypoxanthine incorporation by lactate dehydrogenase assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Synthesis of functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines and evaluation of their antiplasmodial and antifungal activity.
AID1227812Antitumor activity against human MCF7 cells xenografted in BALB/c nude mouse assessed as decrease in tumor volume at 0.023 mmol/kg, ip administered every 2 days for 3 times measured after day 62015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1186057Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS/IFNgamma-induced IL6 production at 0.5 to 4 uM pre-incubated before LPS/IFNgamma challenge and measured 24 hrs post LPS/IFNgamma challenge by ELISA method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1472095Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum Dd2 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID755431Cytotoxicity against human HepG2 cells after 72 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1706810Selectivity index, ratio of IC50 for cytotoxicity against human HepG2 cells to IC50 for antimalarial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Jan-01, Volume: 209Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
AID1751417Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal growth by measuring decrease in OD600 at 100 microM measured after 24 hrs by absorbance based analysis2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID1638536Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1418738Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Synthesis of five libraries of 6,5-fused heterocycles to establish the importance of the heterocyclic core for antiplasmodial activity.
AID1076686Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum and multidrug-resistant human leukemia cells.
AID497991Cmax in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisinin level at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID1771333Antimalarial activity against Plasmodium falciparum Cam3.1 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps, pf-kelch13 mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillati2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID395101Resistance factor, ratio of IC50 for TbAT1 knock out and pentamidine-resistant Trypanosoma brucei brucei B48 mutant to IC50 for wild type Trypanosoma brucei brucei s4272009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
AID1057249Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1423847Antiproliferative activity against human T47D cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID1733339Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID1464216Induction of intracellular ROS production in human HepG2 cells at 30 uM incubated for 10 hrs followed by DCF-DA addition for 20 mins in dark and irradiated with LED light at 1.7 J/cm'2 by fluorescence assay2017Bioorganic & medicinal chemistry letters, 10-01, Volume: 27, Issue:19
Synergistic antiproliferative effect of chemo-phototherapy: Synthesis and photodynamic activity evaluation of novel Chlorin e6-artesunate conjugates as antiproliferative agents.
AID543631Antimicrobial activity against Echinococcus multilocularis metacestode assessed as loss of multicellular structure of germinal layer by transmission electron microscopy2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID523299Antiplasmodial activity against Plasmodium falciparum F32-Tanzania assessed as time required to reach 5% parasitaemia at 9 uM treated for 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.
AID1504885Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1175721Antigametocytocidal activity against Plasmodium falciparum NF54-pfs16-GPF late (4 to 6) gametocyte assessed as viability after 72 hrs by MitoTracker Red CM-H2XRos/micro-plate confocal imaging system2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
AID1714099Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse model assessed as mean survival days at 30 mg/kg, po qd for 4 consecutive days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID1431575Antimalarial activity against Plasmodium falciparum 3D7 asexual blood stage infected in human erythrocytes incubated for 72 hrs by LDH assay2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID1077198Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID276161Antimalarial activity in Plasmodium berghei infected MORO mice (Mus musculus) at 10 mg/kg subcutaneous dose2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID286668Survival of Plasmodium berghei GFP infected mice (Mus musculus) at 30 mg/kg, peroral after three doses2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Malaria-infected mice are cured by a single dose of novel artemisinin derivatives.
AID1639290Selectivity ratio of IC50 for Plasmodium falciparum Dd2 ring stage forms to IC50 for Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1191137Cytotoxicity against human WI38 cells assessed as inhibition of proliferation after 24 hrs by SRB assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID1380019Antiplasmodial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum K1 assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.
AID1186067Inhibition of IKK in mouse BV2 cells assessed as reduction in LPS/IFNgamma-induced IkappaB phosphorylation level at 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by ELISA method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID491637Cell cycle arrest in human CEM/ADR5000 cells assessed as accumulation at G2/M phase 0.01 ug/ml after 48 hrs using propidium iodide staining by flow cytometry2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID759419Cytotoxicity against human BT474 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
AID510909Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID636378Therapeutic index, ratio of MTD for Sprague-Dawley rat to MCD for blood stage of Plasmodium berghei NK652012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID576720Antimalarial activity against Plasmodium falciparum 7G8 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID491633Cytotoxicity against human CCRF-CEM by XTT assay2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID1267694Antiproliferative activity against HUVEC assessed as growth inhibition after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID661141Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as disease cured mouse at 48 mg/kg, im administered once daily for 4 days measured on day2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID1070212Cytotoxicity against CHO cells by MTT assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1450025Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 measured after 72 hrs by DAPI staining based high throughput screening assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID576721Antimalarial activity against Plasmodium falciparum 7G8 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1239478Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities.
AID1353870Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity.
AID286665Survival of Plasmodium berghei GFP infected mice (Mus musculus) at 30 mg/kg, subcutaneous after single dose2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Malaria-infected mice are cured by a single dose of novel artemisinin derivatives.
AID1423845Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID1655967Inhibition of human TOP1B expressed in Saccharomyces cerevisiae EKY3 lacking top1 assessed as reduction in yeast cell growth at 30 uM2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1.
AID1573775Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblasts measured after 7 days by GFP-based multi-round replication assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID585011Antimalarial activity against Plasmodium ovale trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID1633698Selectivity index, ratio of IC50 for CHO cells to IC50 for antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd22019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID1445944Cytotoxicity against human HepG2 cells by CellTiterGlo assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID442260Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1422828Antimalarial activity against Plasmodium berghei N infected in mouse assessed as inhibition of parasitemia at 15 mg/kg, po once daily for 4 consecutive days starting from 2 hrs post infection measured on day 4 post last dose relative to control2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.
AID1732464Antimalarial activity against Plasmodium falciparum 3D7 incubated for 72 hrs by LDH assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
AID728698Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as cured animal at 30 mg/kg, po measured on day 30 postinfection2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID251470Antimalarial activity (10 mg/kg, subcutaneously) given 1 day post infection of mice (Mus musculus) with Plasmodium berghei is its ability to reduce parasitemia on day 3 post infection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1915917Antimalarial activity against Plasmodium berghei infected in mouse assessed as mean survival days at 30 mg/kg, po administered for 4 times starting from 4 to 72 hrs and monitered for 30 days (Rvb = 4 days)
AID728701Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in mouse at 30 mg/kg, po2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID576716Antimalarial activity against Plasmodium falciparum 7G8 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1445953Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as mean survival time at 30 mg/kg, po administered at 4, 24, 48, 72 hrs post infection by Peter's test (Rvb = 6 to 7 day)2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1070209Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive Plasmodium falciparum NF542014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.
AID755428Acute toxicity in human SKHEP1 cells at IC50 after 6 hrs by formazan test2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID491635Cell cycle arrest in human CEM/ADR5000 cells assessed as accumulation at G0/G1 phase 10 ug/ml after 48 hrs using propidium iodide staining by flow cytometry2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID157679In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K12002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID519193Antimicrobial activity against Plasmodium vivax at the ring stage by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID1696501Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth incubated for 72 hrs by DAPI staining based fluorescence analysis2020Journal of natural products, 08-28, Volume: 83, Issue:8
Prenylated Flavonoids from the Roots of
AID568773Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for chloroquine, pyrimethamine, and mefloquine-resistant Plasmodium falciparum Dd22011Journal of natural products, Jan-28, Volume: 74, Issue:1
Phenolic glycosides with antimalarial activity from Grevillea "Poorinda Queen".
AID1616629Antiplasmodial activity against asexual form of Plasmodium falciparum NF54 assessed as reduction in male gametocytes activation preincubated for 48 hrs followed by gametocytes activation and measured after 24 hrs by fluorescence based automated inverted m2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID1616619Antiplasmodial activity against Plasmodium falciparum 3D7A erythrocytic stage assessed as reduction in [3H]hypoxanthine incorporation preincubated for 24 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by microbeta scintillation counti2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1201533Antiplasmodial activity against multi-drug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I dye-based fluorescence assay in presence of ascorbic acid2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1541834Antimalarial activity against asexual stage of Plasmodium falciparum NF54 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay
AID491639Induction of apoptosis in human CEM/ADR5000 cells at 2 ug/mL after 48 hrs using propidium iodide staining by flow cytometry2010Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13
Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells.
AID1160941Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 3 post exposure relative to control2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID1327391Resistance index, ratio of IC50 for chloroquine-resistant asexual erythrocyte stage form Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF542016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID248408In vitro inhibition of chloroquine-resistant Plasmodium falciparum K12005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1733338Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives.
AID442267Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1771305Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 72 hrs by DAPI-staining based imaging analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID576714Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1472098Resistance index, ratio of IC50 for chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum 7G8 to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID157680In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID673149Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 30 mg/kg, po administered 24 hrs post infection qd for 3 days (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1353868Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH release assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity.
AID1552376Antimalarial activity against Plasmodium vinckei petteri 279BY infected in Swiss mouse assessed as reduction in parasitemia administered once daily via intraperitoneal route starting from day 1 to day 4 post infection measured on day 5 Giemsa staining bas2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.
AID1563887Antiplasmodial activity against chloroquine-sensitive asexual blood stage of Plasmodium falciparum NF54 by LDH assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insights.
AID576712Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID1254178Antiplasmodial activity against drug sensitive Plasmodium falciparum NF54 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID543627Antimicrobial activity against Echinococcus granulosus protoscoleces assessed as reduction in protoscoleces viability at 40 uM by trypan blue exclusion assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID1545930Antiproliferative activity against human KB cells by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID482592Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 100 mg/kg, perorally administered as single dose2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID1571714Antiplasmodium activity against multidrug resistant Plasmodium falciparum K1 asexual blood stage forms infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method2019MedChemComm, Mar-01, Volume: 10, Issue:3
Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles.
AID442261Therapeutic index, ratio of IC50 for concanavalin-stimulated BALB/c mice (Mus musculus) splenocytes to IC50 for Plasmodium falciparum 3D72009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID445043Lymphatic organ toxicity in Sprague-Dawley rat at 300 mg/kg, po daily once for 5 days2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID1186068Inhibition of IKK in mouse BV2 cells assessed as reduction in LPS/IFNgamma-induced IkappaB degradation at 0.5 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by ELISA method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1779234Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1162949Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1431587Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP ring stage gametocytes after 24 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID1699386Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability to IC50 for antileishmanial activity against Leishmania donovani MHOM/NP/O2/BPK282/0cl4 promastigote assessed as reduction of2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID1633699Cytotoxicity in CHO cells assessed as reduction in cell viability2019ACS medicinal chemistry letters, May-09, Volume: 10, Issue:5
Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.
AID1162950Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum 3D7 asexual blood stages2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1732472Antimalarial activity against Plasmodium falciparum NF54 early stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
AID1496713Antimalarial activity against Plasmodium berghei infected in mouse assessed as mouse mean survival days at 30 mg/kg, po administered as single dose2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID1661407Antiplasmodial activity against Plasmodium berghei ANKA infected in ip dosed Swiss NMRI mouse assessed as reduction in parasitemia administered once daily for 4 days measured 24 hrs post-last dose by Giemsa-staining based assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
β-Hydroxy- and β-Aminophosphonate Acyclonucleosides as Potent Inhibitors of
AID1186066Inhibition of IKK in mouse BV2 cells assessed as reduction in LPS/IFNgamma-induced IkappaB degradation at 0.5 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1498470Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID755423Cytotoxicity against human SKHEP1 cells incubated for 1 hr prior to hemin addition measured after 72 hrs2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.
AID1197877Antimalarial activity against Plasmodium falciparum infected in SCID mouse engrafted with human erythrocytes assessed as reduction in parasitemia at 5 mg/kg, po qd for 4 days relative to control2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Prodrugs of reverse fosmidomycin analogues.
AID605904Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as mouse survival at 100 mg/kg, po administered as single dose 24 hrs post infection measured on day 30 post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID543629Antimicrobial activity against Echinococcus multilocularis metacestode assessed as increase in alkaline phosphatase activity at 40 uM within 4 days2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.
AID728700Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected mouse assessed as reduction in parasitemia at 30 mg/kg, po measured on day 3 postinfection relative to control2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1304206Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID1513841Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes preincubated for 48 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by liquid scintillation counting2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.
AID1128659Antimalarial activity against GFP-transfected Plasmodium berghei ANKA infected in mouse assessed as mean survival days at 30 mg/kg, po qd for 4 days2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.
AID1915914Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction in parasitemia in blood at 30 mg/kg, po administered for 4 times starting from 4 to 72 hrs and measured after 96 hrs post infection (Rvb = 0%)
AID1186063Inhibition of IKK in mouse BV2 cells assessed as LPS/IFNgamma-induced IkappaB phosphorylation level at 1 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1227804Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID1546492Antitumour activity against human PANC1 cells xenografted in ip dosed nude BALB/c mouse assessed as tumor weight for 18 days2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID482591Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as host survival time at 30 mg/kg, perorally administered as single dose (Rvb = 6 to 7 days)2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
AID1186070Inhibition of LPS/IFNgamma-induced IKKbeta phosphorylation in mouse BV2 cells at 1 to 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1155338Antimalarial activity against late stage gametocyte stage of Plasmodium falciparum NF54 after 72 hrs2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID443097Antimalarial activity against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) assessed as reduction of parasitemia at 10 mg/kg, perorally 4 consecutive doses for 3 days measured on day 4 by FACS analysis2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1415896Cytotoxicity against CHO cells by MTT assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID1227805Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell viability after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
The biological characteristics of a novel camptothecin-artesunate conjugate.
AID1162947Antiplasmodial activity against Plasmodium falciparum Dd2 asexual blood stages after 3 days by HRP2 detection based ELISA method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID748940Half life in human2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1751424Potentiation of fluconazole-induced antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal filamentation by measuring reduction in fungal hyphae growth in Spider medium at 100 uM incubated for 1 hr in presence of fluconazole 2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID1546526Antitumour activity against mouse H22 cells transplanted in mouse assessed as tumour growth inhibition at 300 mg/kg after 7 days relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1771332Antimalarial activity against Plasmodium falciparum TM90C2b harbouring Pf-crt, Pf-mdrl,Pfd-hfr, Pf-cytbQ0 mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counti2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID1723649Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Expanding the scope of synthetic 1,2,4-trioxanes towards Trypanosoma cruzi and Leishmania donovani.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID576576Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID661138Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as suppression of parasitemia at 12 mg/kg, im administered once daily for 4 days relative2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID519190Antimicrobial activity against Plasmodium vivax trophozoites by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID605903Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as mouse survival at 30 mg/kg, po administered as single dose 24 hrs post infection measured on day 30 post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID585010Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID1423841Antimalarial activity against synchronized ring stage of Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green1 dye based fluorescence assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID1546490Cytotoxicity against human PANC1 cells assessed as cell viability after 24 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID673147Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as increase of mouse survival at 30 mg/kg, po administered 24 hrs post infection (Rvb = 6 to 7 days)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID1277750Antiparasitic activity against chloroquine/quinine/pyrimethamine/sulfadoxine/NITD609-resistant Plasmodium falciparum Dd2 clone 2 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
AID1437497Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID276163Survival of MORO mice (Mus musculus) infected with Plasmodium berghei at 10 mg/kg, subcutaneously after 30 day post-infection2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
AID277708Survival of Swiss mice (Mus musculus) infected with Plasmodium yoelii nigeriensis at 24 mg/kg, peroral after 28 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID1524521Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
AID1070210Antiplasmodial activity chloroquine-resistant Plasmodium falciparum Dd2 by lactate dehydrogenase assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.
AID1186065Inhibition of IKK in mouse BV2 cells assessed as LPS/IFNgamma-induced IkappaB phosphorylation level at 4 uM pre-incubated for 30 mins before LPS/IFNgamma challenge for 1 hr by Western blot method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1186060Inhibition of NFkappaB (unknown origin) expressed in HEK293 cells assessed as reduction in TNFalpha-induced gene transcription at 0.5 to 4 uM pre-incubated for 30 mins prior to stimulation with TNFalpha for 6 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNγ-activated BV2 microglia.
AID1541831Antimalarial activity against asexual stage of Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID1445973Gametocytocidal activity against GFP-fused Plasmodium berghei liver stage gametocytes infected in human HepG2-A16-CD81-EGFP cells after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1541837Antimalarial activity against Plasmodium falciparum NF54 early gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1437506Selectivity index, ratio of growth inhibitory effect against HEK293 cells at 20 uM to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC
AID1462232Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based fluorescence microscopic analysis2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID444926Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction of parasitaemia level at 10 mg/kg, perorally administered 1 day after post-infection measured after 3 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID658603Antiplasmodial activity chloroquine-sensitive Plasmodium falciparum 3D7 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 24 hrs by scintillation counting2012European journal of medicinal chemistry, Jun, Volume: 522-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID444928Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as mice (Mus musculus) survival days at 3 mg/kg, perorally daily once for 3 consecutive days measured after 4 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID586613Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID768213Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd22013European journal of medicinal chemistry, Aug, Volume: 66Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID576718Antimalarial activity against Plasmodium falciparum 7G8 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID285473Cytotoxicity against human HCT cells assessed as [3H]thymidine incorporation2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID1327388Thermal stability of the compound assessed as melting point by thermogravimetric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.
AID1277743Antiparasitic activity against Plasmodium falciparum Dd2 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
AID1587110Anti-plasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 72 hrs by SYBR green dye based fluorescence assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID1267704Induction of apoptosis in human K562/ADR cells assessed as early apoptotic cells at 6.5 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 1.49%)2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1541832Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID1524518Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
AID673144Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in NMRI mouse assessed as reduction of parasite level in blood at 100 mg/kg, po administered 24 hrs post infection measured after 72 hrs post infection by flow cytometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.
AID510949Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 962010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID321286Reduced parasitemia in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose after 4 days2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID1440393Antibiofilm activity against Candida albicans SC5314 after 24 hrs in presence of miconazole by Cell-Titer Blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1437499Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID1498473Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in primary HFF2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1191136Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum W2 to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.
AID1267719Induction of apoptosis in human K562/ADR cells assessed as nuclear condensation at 6.5 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1235982Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF54 assessed as parasite growth inhibition by parasite lactate dehydrogenase assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine.
AID1529413Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by 2018MedChemComm, Oct-01, Volume: 9, Issue:10
Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.
AID618228Antiparasitic activity against Fasciola hepatica infected in rat assessed as reduction in worm burden at 100 mg/kg, po administered as single dose measured after 6 days post treatment2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
The activity of dispiro peroxides against Fasciola hepatica.
AID1235983Resistance index, ratio of IC50 for chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF542015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine.
AID1472107Inhibition of beta hematin formation by detergent based assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID576715Antimalarial activity against Plasmodium falciparum 7G8 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
AID286667Survival of Plasmodium berghei GFP infected mice (Mus musculus) at 3 mg/kg, subcutaneous after single dose2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Malaria-infected mice are cured by a single dose of novel artemisinin derivatives.
AID1423846Antiproliferative activity against human MDA-MB-361 cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Nov-08, Volume: 9, Issue:11
Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV,
AID1546476Cytotoxicity against human U2OS cells assessed as cell viability after 48 hrs in presence of allicin by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID285472Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcM292007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID759416Selectivity index, ratio of IC50 for human MCF10A cells to IC50 for human BT474 cells2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
AID1304204Resistance index, ratio of IC50 for multi-drug-resistant Plasmodium falciparum K1 infected in human erythrocytes to IC50 for chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities.
AID247109Effective dose required to reduce the parasitemia in mice when compound administered with Tween-80 after 3 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1546471Cytotoxicity against human BGC823 assessed as cell viability at 160 mg/l after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1076685Resistance ratio of IC50 for human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein to IC50 for human CCRF-CEM cells2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum and multidrug-resistant human leukemia cells.
AID1254195Antiplasmodial activity against Plasmodium berghei ANKA expressing GFP infected in mouse assessed as reduction of parasitemia level at 30 mg/kg, po qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID442264Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT10500 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1243885Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum NF54 by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Primaquine-pyrimidine hybrids: synthesis and dual-stage antiplasmodial activity.
AID497993Cmax in Ugandan children patient with uncomplicated malaria at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID586609Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID605814Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po administered as single dose 24 hrs post infection measured 72 hrs post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID1327028Antiplasmodial activity against erythrocytic stage of chloroquine/pyrimethamine/cycloguanil resistant-Plasmodium falciparum FCR3 after 48 hrs by [3H]-hypoxanthine incorporation assay2016European journal of medicinal chemistry, Oct-21, Volume: 1224-Aminoquinoline derivatives: Synthesis, in vitro and in vivo antiplasmodial activity against chloroquine-resistant parasites.
AID452987Antimalarial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered 1 day post infection2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID453155Lipophilicity, log D at pH 7.42010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID1445945Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for chloroquine-sensitive asexual blood stages of Plasmodium falciparum 3D72017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID113355In vivo effective dose was evaluated against Plasmodium berghei N by sub cutaneous administration in mice (Mus musculus)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Orally active antimalarials: hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydroartemisinin.
AID1422831Antimalarial activity against Plasmodium berghei N infected in mouse assessed as mouse survival at 15 mg/kg, po once daily for 4 consecutive days starting from 2 hrs post infection relative to control2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.
AID1699397Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability to IC50 for antileishmanial activity against Leishmania donovani amastigotes infected in human THP1 cells assessed as reducti2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.
AID682364Selectivity ratio of IC50 for human CEM/ADR5000 cells to IC50 for human CCRF-CEM cells2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells.
AID1779235Selectivity index, ratio of IC50 for antimalarial activity against Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID510914Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID704025Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HeLa cells2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID605902Antimalarial activity against GFP-tagged Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po QD administered 24 hrs post infection for 3 days measured on day 4 post infection2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID1404599Cytotoxicity against HEK293 cells assessed as inhibition of cell growth at 20 uM after 72 hrs by alamar blue assay relative to control2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microthecaline A, a Quinoline Serrulatane Alkaloid from the Roots of the Australian Desert Plant Eremophila microtheca.
AID1353869Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 by LDH release assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity.
AID1714085Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by liquid2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.
AID510947Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia dosed in 7% Tween80/3% ethanol formulation 1 day post infection measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1247862Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 by [3H]-hypoxanthine incorporation assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
AID1648008Selectivity ratio of IC50 for HEK293 cells to IC50 for antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd22020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID247108Effective dose required to reduce the parasitemia in mice when compound administered with SSV after 3 day postinfection2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
AID1201063Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SKF582015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID1247861Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 by [3H]-hypoxanthine incorporation assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
AID452989Antimalarial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as survival time at 3 mg/kg, perorally administered for 3 days post infection2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID1639288Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-sensitive Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1751422Antifungal activity against Candida albicans SC5314 assessed as inhibition of fungal filamentation in Spider medium at 100 uM incubated for 1 hr by microscopic analysis2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5.
AID1462240Selectivity index, ratio of IC50 for HEK293 cells to IC50 for Plasmodium falciparum 3D72017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (191)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (1.57)18.2507
2000's30 (15.71)29.6817
2010's131 (68.59)24.3611
2020's27 (14.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.52%)5.53%
Reviews13 (6.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other178 (92.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (209)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon [NCT00297882]Phase 3816 participants (Actual)Interventional2006-07-31Completed
Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients [NCT04374019]Phase 213 participants (Actual)Interventional2020-05-01Terminated(stopped due to slow accrual,)
Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine [NCT04713631]Phase 240 participants (Anticipated)Interventional2021-01-21Recruiting
Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, the Standard Treatment Recommended by the Ministry of the Social Protection in Colombia for the Treatment of Uncompl [NCT04877626]Phase 4210 participants (Actual)Interventional2008-09-30Completed
A Multi-Center Single Arm, Open-label, Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients [NCT05633420]Phase 220 participants (Actual)Interventional2022-07-24Completed
Study to Determine the Efficacy of Artesunate-mefloquine Combination Therapy for the Treatment of Uncomplicated P. Falciparum Malaria in Thailand [NCT02052323]Phase 448 participants (Actual)Interventional2013-10-31Completed
Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Treatment of Severe Malaria in Ugandan Patients [NCT01122134]20 participants (Anticipated)Observational2010-05-31Not yet recruiting
Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup [NCT01288820]Phase 3331 participants (Actual)Interventional2011-01-31Completed
A Randomized, Open-Label Exploratory Study To Determine The Efficacy Of Different Treatment Regimens Of Pyramax® (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections [NCT03814616]Phase 2300 participants (Actual)Interventional2018-10-03Active, not recruiting
A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar [NCT03768908]Phase 4359 participants (Actual)Interventional2005-01-05Completed
A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria. [NCT01350856]Phase 41,700 participants (Actual)Interventional2011-05-31Completed
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich Ataxia [NCT04921930]Phase 1/Phase 220 participants (Anticipated)Interventional2022-05-06Recruiting
A Phase III Randomised, Double-blind, Double-dummy, Comparative Study to Assess the Safety and Efficacy of Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children and Adult Patients in Korea With Acute P. Vivax Malaria [NCT04368910]Phase 330 participants (Actual)Interventional2007-09-06Terminated(stopped due to Due to slow recruitment the study was terminated prematurely by the Sponsor after 30 subjects had been included)
Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan [NCT01115439]100 participants (Actual)Observational2010-03-31Completed
Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial [NCT01231113]Phase 3417 participants (Actual)Interventional2011-07-31Completed
A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children [NCT03893097]Phase 3726 participants (Actual)Interventional2019-10-14Completed
Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia. [NCT01319448]Phase 1/Phase 2270 participants (Actual)Interventional2011-09-30Completed
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Suppositories for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL) [NCT05555862]Phase 248 participants (Anticipated)Interventional2023-02-10Recruiting
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3) [NCT04098744]Phase 278 participants (Anticipated)Interventional2020-09-09Recruiting
Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh [NCT01374126]Phase 275 participants (Actual)Interventional2011-07-31Completed
Open-label, Drug Interaction Study of Pyronaridine-artesunate and Metoprolol in Healthy Volunteers and Pyronaridine-artesunate Redosing Study in Healthy Volunteers [NCT01523002]Phase 156 participants (Actual)Interventional2012-01-31Completed
Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia [NCT03726593]Phase 4252 participants (Anticipated)Interventional2018-10-04Recruiting
Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon [NCT02084602]Phase 445 participants (Actual)Interventional2014-06-18Completed
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border [NCT01074905]Phase 3655 participants (Actual)Interventional2010-05-31Completed
Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria [NCT02092766]Phase 4217 participants (Actual)Interventional2014-06-30Completed
A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains [NCT01374581]Phase 32,117 participants (Actual)Interventional2012-05-31Completed
Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam [NCT01165372]Phase 2166 participants (Actual)Interventional2010-08-31Completed
Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar [NCT03773536]Phase 4146 participants (Actual)Interventional2017-05-09Completed
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection [NCT01082718]Phase 2/Phase 30 participants (Actual)Interventional2010-03-31Withdrawn(stopped due to Logistical difficulties)
A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Idiopathic Pulmonary Fibrosis [NCT05988463]Phase 110 participants (Anticipated)Interventional2024-02-01Not yet recruiting
Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax® [NCT03201770]Phase 48,572 participants (Actual)Interventional2017-06-22Completed
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A [NCT03640403]Phase 31,555 participants (Actual)Interventional2019-03-26Active, not recruiting
A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon [NCT02563704]Phase 3238 participants (Actual)Interventional2013-09-30Completed
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children [NCT00393679]Phase 34,112 participants (Actual)Interventional2007-07-31Completed
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL) [NCT06075264]Phase 227 participants (Anticipated)Interventional2023-12-06Recruiting
Comparing Safety and Protective Efficacy of the Whole Plasmodium Falciparum Sporozoite Chemoprophylaxis Vaccine Candidate PfSPZ-CVac and Prime- Target Vaccination With Viral Vectored Vaccine Candidate Regime MVA ME-TRAP/ ChAd63 ME-TRAP in Malaria-naïve, H [NCT05441410]Phase 1/Phase 230 participants (Anticipated)Interventional2024-02-01Not yet recruiting
Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania [NCT03431714]Phase 4333 participants (Actual)Interventional2017-07-14Completed
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009. [NCT01144702]Phase 2/Phase 3163 participants (Actual)Interventional2010-11-30Completed
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil [NCT01107145]Phase 416 participants (Actual)Interventional2011-02-28Terminated(stopped due to Extremely slow enrollment)
An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium [NCT04675931]Phase 2252 participants (Anticipated)Interventional2022-03-07Recruiting
Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplica [NCT05689047]Phase 2137 participants (Anticipated)Interventional2023-03-29Recruiting
Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial [NCT01152931]Phase 310 participants (Actual)Interventional2010-08-31Completed
Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi [NCT01190371]Phase 4175 participants (Actual)Interventional2011-04-30Active, not recruiting
Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso [NCT01213433]Phase 4150 participants (Actual)Interventional2010-10-31Completed
Efficacy of the Artesunate-amodiaquine Combination for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Between 6 and 59 Months of Age With Severe Acute Malnutrition in Madaoua, Tahoua Region, Niger [NCT01204411]Phase 40 participants (Actual)InterventionalWithdrawn(stopped due to The ethics committee did not approve the pharmacokinetic part of the study.)
A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal [NCT00540410]Phase 4366 participants (Actual)Interventional2007-09-30Completed
Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar [NCT03764527]Phase 4408 participants (Actual)Interventional2002-11-01Completed
A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria [NCT01378286]Phase 3380 participants (Actual)Interventional2012-01-31Completed
Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria [NCT00902811]Phase 4600 participants (Anticipated)Interventional2008-12-31Recruiting
Artemisinin Resistance in Bangladesh [NCT00639873]126 participants (Actual)Interventional2008-06-30Completed
Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia [NCT06166498]Phase 3600 participants (Anticipated)Interventional2024-02-15Not yet recruiting
A Multicenter, Prospective, Observational Study to Assess the Efficacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC) [NCT02640495]0 participants (Actual)Observational2015-10-31Withdrawn(stopped due to Due to the relative low incidence of severe malaria in Southeast Asia.)
Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection [NCT04264130]Phase 254 participants (Actual)Interventional2018-07-31Completed
The Pharmacokinetic of the Fixed-dose Combination of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnant Women [NCT00701961]Phase 2/Phase 348 participants (Actual)Interventional2008-10-31Completed
In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso [NCT00808951]Phase 4440 participants (Actual)Interventional2008-12-31Completed
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial (TES2022) [NCT06076213]Phase 41,408 participants (Anticipated)Interventional2023-05-01Recruiting
Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Mal [NCT01326754]498 participants (Actual)Interventional2011-08-31Completed
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients [NCT04475107]Phase 2113 participants (Actual)Interventional2020-07-09Completed
A Five-arm Trial Comparing Artesunate-amodiaquine and Artemether-lumefantrine-amodiaquine With or Without Single-dose Primaquine to Reduce P. Falciparum Transmission in Mali [NCT05550909]Phase 2100 participants (Actual)Interventional2022-10-17Completed
Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate [NCT02242799]Phase 146 participants (Actual)Interventional2015-06-30Completed
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite, Open-label, Two-cohort Clinical Trial in Mozambique. [NCT02168569]Phase 4700 participants (Actual)Interventional2011-06-30Completed
A Single-Dose Bioequivalence Study Comparing Artesunate Tablet (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects [NCT00894374]Phase 140 participants (Actual)Interventional2009-06-30Completed
A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil [NCT01082731]Phase 46 participants (Actual)Interventional2010-11-30Terminated(stopped due to Extremely slow enrollment)
An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium F [NCT00444106]Phase 4265 participants (Actual)Interventional2007-05-31Completed
A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enro [NCT01023399]Phase 4580 participants (Actual)Interventional2009-11-30Completed
A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria [NCT00440999]Phase 3456 participants (Actual)Interventional2007-03-31Completed
A Phase II, Randomized, Open-Label, Dose-Ranging Study of Intravenous Artesunate Therapy for the Treatment of Acute, Uncomplicated Plasmodium Falciparum Malaria. [NCT00459615]Phase 2120 participants (Anticipated)Interventional2007-04-30Completed
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar [NCT00465257]Phase 4110 participants (Anticipated)Interventional2007-05-31Suspended(stopped due to Due to lack of malaria patients in Zanzibar the study has been suspended.)
A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar [NCT02792816]550 participants (Actual)Observational2009-06-30Completed
In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo [NCT02741024]Phase 4288 participants (Actual)Interventional2013-10-31Completed
Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine [NCT00509015]6,000 participants (Anticipated)Interventional2008-02-29Completed
Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PfSPZ Vaccine in Malaria-Experienced Adults in [NCT02663700]Phase 1112 participants (Actual)Interventional2016-04-07Completed
Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plas [NCT00988507]Phase 2440 participants (Anticipated)Interventional2009-10-31Terminated(stopped due to Company decision to modify the ferroquine development strategy; discontinuation not due to safety or activity unexpected findings)
Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations [NCT02653898]Phase 41,050 participants (Actual)Interventional2016-01-31Active, not recruiting
Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan [NCT00682578]Phase 31,086 participants (Actual)Interventional2007-07-31Completed
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With th [NCT04330690]Phase 32,900 participants (Anticipated)Interventional2020-03-18Active, not recruiting
Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western [NCT00936767]Phase 2/Phase 30 participants (Actual)Interventional2010-10-31Withdrawn(stopped due to Did not get approval)
A Phase 1 Double-Blind, Placebo-Controlled, Randomized Multiple Dose Escalation Study to Evaluate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of a New GMP Formulation of Intravenous Artesunate if Healthy Subjects [NCT00292942]Phase 126 participants (Actual)Interventional2006-06-12Completed
Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT00541385]Phase 3535 participants (Actual)Interventional2007-10-31Completed
Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy [NCT01017770]Phase 4340 participants (Anticipated)Interventional2008-09-30Completed
A Randomized Trial of Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria in Tanzanian Children. [NCT00694694]Phase 3261 participants (Actual)Interventional2008-06-30Completed
A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adoles [NCT00344006]Phase 31,395 participants (Actual)Interventional2006-06-30Completed
An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combi [NCT05951595]Phase 31,440 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate [NCT05929157]Phase 1/Phase 212 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam [NCT02604966]Phase 4120 participants (Anticipated)Interventional2015-04-30Recruiting
Very Severe Malaria Treated by Intravenous Artesunate: Epidemiology, Management, Outcome and Prognostic [NCT04516317]578 participants (Actual)Observational2020-08-10Completed
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria [NCT00852423]Phase 33,428 participants (Actual)Interventional2010-06-30Completed
Validation of the Use of Istope-Based Molecular Techniques for Malaria Control [NCT00646126]Phase 30 participants Interventional2005-08-31Completed
The Clinical Impact of Seasonal Intermittent Preventive Treatment (IPT) and Home Management of Malaria (HMM) Using AQ+AS in Ghanaian Children Under 5 Years of Age - a Cluster Randomised Placebo Controlled Trial. [NCT00550160]Phase 41,490 participants (Actual)Interventional2007-04-30Completed
The Efficacy and Safety of Pyronaridine-artesunate Combined With Low Dose Primaquine for Preventing Transmission of P. Falciparum Gametocytes in Sub-Saharan Africa [NCT04049916]Phase 2/Phase 3100 participants (Actual)Interventional2019-09-12Completed
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03939104]Phase 31,368 participants (Anticipated)Interventional2021-06-30Recruiting
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03923725]Phase 33,240 participants (Anticipated)Interventional2020-09-01Recruiting
Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children [NCT01407887]Phase 2180 participants (Actual)Interventional2011-08-31Completed
A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa [NCT00978172]Phase 4220 participants (Actual)Interventional2007-12-31Completed
Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children [NCT01054651]Phase 3212 participants (Actual)Interventional2009-10-31Completed
Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer [NCT00764036]Phase 123 participants (Actual)Interventional2008-10-31Completed
Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan [NCT00959517]Phase 2588 participants (Actual)Interventional2001-07-31Completed
A Randomized, Open-Label, Cross-Over Study, to Compare the Bioavailability of the Fixed Combination of Amodiaquine and Artesunate (COARSUCAM™) After Single Oral Administration Under Fed and Fasted Conditions in Healthy Subjects [NCT00386503]Phase 122 participants Interventional2006-06-30Completed
A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria [NCT00403260]Phase 31,271 participants (Actual)Interventional2007-01-31Completed
A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria [NCT00422084]Phase 31,272 participants (Actual)Interventional2007-01-31Completed
An Open-label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) in Children With Acute Falciparum Malaria [NCT00331136]Phase 260 participants (Actual)Interventional2006-06-30Completed
Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2) [NCT01939886]Phase 3219 participants (Actual)Interventional2013-04-30Completed
Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone [NCT01967472]1,145 participants (Actual)Interventional2013-09-16Completed
In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya [NCT01976780]Phase 4118 participants (Actual)Interventional2013-06-30Completed
Monitoring the Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine During the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in Yaounde, Cameroon [NCT04565184]Phase 4242 participants (Actual)Interventional2019-05-09Completed
Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 [NCT04532931]Phase 2192 participants (Actual)Interventional2020-09-03Completed
Artemisinin Resistance in Cambodia II [NCT00722150]143 participants (Actual)Interventional2008-07-31Completed
Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers [NCT01156389]Phase 134 participants (Actual)Interventional2010-07-31Completed
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014 [NCT02637128]Phase 4452 participants (Actual)Interventional2014-03-31Completed
Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children [NCT00612547]1,200 participants (Actual)Observational2008-02-29Completed
Phase I Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo [NCT00538382]Phase 151 participants (Actual)Interventional2007-05-31Completed
Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer [NCT02633098]Phase 2200 participants (Anticipated)Interventional2017-04-26Recruiting
Evaluation of the Efficacy and Effectiveness of Combined Therapy With Mefloquine and Artesunate for Uncomplicated Malaria Treatment in the Loreto Region (Amazon Basin), Peru [NCT00164216]208 participants (Actual)Observational2005-03-31Completed
Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum [NCT00164255]Phase 41,614 participants (Actual)Interventional2003-01-31Completed
Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections [NCT00203736]240 participants Interventional2003-01-31Completed
Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carr [NCT00203814]280 participants Interventional2004-01-31Completed
A Single-Dose Bioequivalence Study Comparing Artesunate Sachets (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects [NCT00875030]Phase 440 participants (Actual)Interventional2009-06-30Completed
Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19 [NCT04387240]Phase 20 participants (Actual)Interventional2022-01-31Withdrawn(stopped due to did not get enough fund and IRB request)
Phase I, Randomized, Single Dose, Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet [NCT00682630]Phase 142 participants (Actual)Interventional2007-09-30Completed
Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack [NCT00445796]Phase 4300 participants Interventional2005-06-30Completed
Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria of Infectious, Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Chemoprophylaxi [NCT02996695]Phase 162 participants (Actual)Interventional2017-04-06Completed
[NCT00354380]Phase 20 participants Interventional2006-09-30Completed
Randomized Double Blind Clinical Trial in Mali, Comparing the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel in the Treatment of S. Haematobium in Children [NCT00510159]Phase 2/Phase 3800 participants (Actual)Interventional2007-08-31Completed
Phase II Randomized, Double-Blind Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous Artesunate in Children With Severe Malaria [NCT00522132]Phase 2200 participants (Anticipated)Interventional2007-09-30Completed
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso [NCT04695197]Phase 3142 participants (Anticipated)Interventional2021-01-08Recruiting
An Open, Randomised, Multi-centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate [NCT00519467]Phase 2120 participants (Actual)Interventional2003-06-30Completed
Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 [NCT01755559]Phase 4663 participants (Actual)Interventional2013-06-30Completed
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study [NCT03214731]Phase 490 participants (Anticipated)Interventional2019-01-16Recruiting
Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy [NCT00123552]Phase 3601 participants (Actual)Interventional2004-11-30Completed
An Open-label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria [NCT00331708]3 participants (Actual)Interventional2006-04-30Terminated(stopped due to Lack of suitable participants)
Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali [NCT00127998]1,011 participants Interventional2005-07-31Completed
The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial. [NCT00432367]Phase 33,333 participants (Actual)Interventional2007-02-28Completed
A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa [NCT00132561]Phase 2/Phase 31,200 participants Interventional2002-06-30Completed
Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study [NCT00460369]240 participants (Actual)Interventional2007-04-30Completed
Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children [NCT00461578]800 participants Interventional2005-04-30Completed
Artemisinin Resistance in Cambodia [NCT00479206]0 participants Interventional2006-10-31Completed
A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana [NCT00119132]Phase 2/Phase 32,602 participants (Actual)Interventional2005-06-30Completed
A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. [NCT00486694]Phase 2190 participants (Actual)Interventional2004-03-31Completed
A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana [NCT00119145]Phase 4510 participants (Anticipated)Interventional2005-06-30Completed
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia [NCT00493363]40 participants (Actual)Interventional2007-06-30Completed
Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children [NCT00140361]Phase 4390 participants (Actual)Interventional2000-01-31Completed
A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children [NCT00132548]Phase 32,200 participants Interventional2004-06-30Completed
[NCT00406146]Phase 30 participants Interventional2004-10-31Active, not recruiting
Can Triple Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria, Delay Drug Resistance Development of Plasmodium Falciparum in Tanzania: a Randomized Three Arm Clinical Trial [NCT05764746]Phase 2/Phase 3384 participants (Anticipated)Interventional2023-04-01Not yet recruiting
Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan [NCT01805232]Phase 480 participants (Anticipated)Interventional2013-03-31Recruiting
Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544 [NCT00545935]Phase 2186 participants Interventional2007-07-31Completed
A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy [NCT01054248]Phase 3511 participants (Actual)Interventional2010-02-16Completed
Open Label Study to Evaluate Combination Anti-malarial Therapy,in Terms of Efficacy, Prevalence of Gametocyte Carriage and Molecular Markers Associated With Sulfadoxine Pyrimethamine Resistance in Uncomplicated Plasmodium Falciparum [NCT00203801]700 participants Interventional2002-01-31Completed
A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria [NCT00238017]Phase 4400 participants Interventional2005-10-31Active, not recruiting
Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan [NCT00330902]Phase 3104 participants (Actual)Interventional2004-01-31Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (Artecom®) in COVID-19 Patients [NCT04701606]Phase 2/Phase 3402 participants (Anticipated)Interventional2021-03-29Recruiting
Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali [NCT00452907]Phase 4780 participants (Actual)Interventional2005-07-31Completed
Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria [NCT05192265]Phase 2/Phase 3172 participants (Actual)Interventional2019-05-20Completed
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial [NCT02940756]Phase 41,615 participants (Actual)Interventional2017-03-15Completed
Efficacy and Safety of Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Center Region of Cameroon [NCT04829695]Phase 4184 participants (Anticipated)Interventional2021-04-05Not yet recruiting
Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM) [NCT01640587]76 participants (Actual)Interventional2013-11-30Terminated(stopped due to No adequate malaria patient)
Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia [NCT00378625]Phase 3360 participants Interventional2000-04-30Completed
Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects [NCT01552330]Phase 117 participants (Actual)Interventional2012-05-31Completed
Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya [NCT00111163]1,516 participants Interventional2004-03-31Completed
Randomized Trial of the Effectiveness of Amodiaquine-Artesunate, Amodiaquine-Sulfadoxine-Pyrimethamine, and Chloroquine-Sulfadoxine-Pyrimethamine, for Treatment of Uncomplicated Malaria in Gambian Children [NCT00118807]Phase 31,800 participants Interventional2003-08-31Completed
Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania [NCT00146731]Phase 3310 participants (Actual)Interventional2004-01-31Completed
A Randomized Trial to Compare the Efficacy of Artekin and Amodiaquine Plus Artesunate for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua [NCT00157885]400 participants Interventional2005-07-31Completed
Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan [NCT00158548]Phase 3650 participants (Actual)Interventional2001-06-30Completed
A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi [NCT00164359]Phase 4212 participants Interventional2005-04-30Completed
An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi [NCT00164710]Phase 4365 participants Interventional2005-04-30Completed
A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria [NCT00298610]Phase 230 participants (Actual)Interventional2006-03-31Completed
Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria [NCT01955382]Phase 270 participants (Actual)Interventional2013-09-30Completed
Age of Exposure and Immunity to Malaria in Infants [NCT00231452]349 participants (Actual)Interventional2005-09-30Completed
Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria [NCT00243737]Phase 270 participants Interventional2005-10-31Completed
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Artesunate Administered to Healthy Subjects [NCT00292929]Phase 140 participants InterventionalCompleted
Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria [NCT00299208]Phase 2120 participants InterventionalCompleted
Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the T [NCT00316329]Phase 31,032 participants Interventional2006-03-31Completed
Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients [NCT00284687]Phase 320 participants (Anticipated)Interventional2006-07-31Completed
Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants [NCT00285662]1,100 participants (Anticipated)Interventional2006-06-30Completed
A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy [NCT00287300]141 participants Interventional2003-09-30Completed
Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum: A Randomized Controlled Trial [NCT00289250]Phase 3360 participants Interventional2001-05-31Completed
Self-administered Artesunate Pessaries for Treatment of Cervical Precancer in Kenya [NCT06165614]Phase 118 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand [NCT01659281]13 participants (Actual)Interventional2007-09-30Completed
An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand [NCT01662700]Phase 4120 participants (Anticipated)Interventional2012-10-31Recruiting
WHO Solidarity Trial Plus: An International Randomised Trial of Additional Treatments for COVID-19 in Hospitalised Patients Who Are All Receiving the Local Standard of Care in Nepal [NCT05273242]Phase 4400 participants (Anticipated)Interventional2021-12-06Recruiting
Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso [NCT01697787]Phase 4150 participants (Actual)Interventional2012-10-31Completed
Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan [NCT01707199]83 participants (Actual)Interventional2012-10-31Completed
Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia [NCT01708876]Phase 3250 participants (Anticipated)Interventional2012-10-31Completed
Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon [NCT01845701]Phase 3720 participants (Actual)Interventional2010-03-31Completed
A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria [NCT00374205]Phase 4245 participants (Actual)Interventional2006-09-30Terminated(stopped due to Interim analysis showed more LCFs in one of the treatment arms)
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure [NCT04706130]Phase 4200 participants (Anticipated)Interventional2021-04-15Recruiting
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) [NCT04778813]Phase 41,050 participants (Anticipated)Interventional2021-06-01Not yet recruiting
"Prospective Longitudinal Study of Interactions Between HIV and Malaria in Ugandan Children: A UCSF/Makerere University Children With HIV and Malaria Project" [NCT00356824]300 participants (Anticipated)Observational2005-11-30Completed
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya [NCT02411994]Phase 3197 participants (Actual)Interventional2015-10-31Completed
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite Open Label, Two-cohort Clinical Trial in Mozambique [NCT04370977]Phase 4630 participants (Actual)Interventional2018-03-21Completed
A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults [NCT00371735]Phase 3900 participants (Actual)Interventional2006-04-30Completed
Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region [NCT00373607]Phase 3522 participants (Actual)Interventional2003-07-31Completed
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3) [NCT02354534]Phase 130 participants (Actual)Interventional2015-02-28Completed
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial [NCT00356005]Phase 2228 participants (Actual)Interventional2006-08-31Completed
A Phase I Study of Intravenous Artesunate in Patients With Solid Tumors [NCT02353026]Phase 119 participants (Actual)Interventional2015-01-31Completed
A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi [NCT00379821]Phase 3640 participants (Actual)Interventional2007-02-28Completed
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial [NCT04618523]Phase 41,117 participants (Actual)Interventional2020-10-26Completed
Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer in Vietnamese Patients [NCT03093129]Phase 2200 participants (Anticipated)Interventional2018-01-08Recruiting
Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria [NCT02389439]Phase 2123 participants (Actual)Interventional2015-03-01Completed
Convenience and Cost-aspects of a New 1-step Reconstitution Injectable Artesunate Compared to Conventional 2-step Injectable Artesunate for the Treatment of Severe Falciparum Malaria: a Multi-centre Study [NCT05140278]Phase 2200 participants (Actual)Interventional2022-07-18Completed
A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) [NCT03100045]Phase 118 participants (Actual)Interventional2017-04-20Completed
A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT01594931]Phase 2477 participants (Actual)Interventional2005-07-31Completed
Exposure-Response Evaluation of IV Artesunate in Children With Severe Malaria [NCT05750459]Phase 4100 participants (Anticipated)Interventional2023-11-29Recruiting
[NCT02492178]Phase 282 participants (Actual)Interventional2015-07-31Completed
Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers [NCT01868438]Phase 160 participants (Actual)Interventional2013-05-31Completed
Phase I Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Oral Artesunate (ART) in Patients With Advanced Hepatocellular Carcinoma (HCC). [NCT02304289]Phase 12 participants (Actual)Interventional2014-11-30Terminated(stopped due to slow recruitment of patients)
Therapeutic Efficacy of Atovaquone-proguanil and Artesunate-atovaquone-proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Areas of Multidrug Resistance in Cambodia. [NCT02297477]Phase 4205 participants (Actual)Interventional2014-12-31Active, not recruiting
A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3) [NCT03792516]Phase 115 participants (Actual)Interventional2019-04-17Active, not recruiting
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]Phase 3300 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00292942 (8) [back to overview]Cardiovascular Responses: Number of Participants With Changes in Blood Pressure and Heart Rate After Infusion
NCT00292942 (8) [back to overview]Number of Participants With AEs
NCT00292942 (8) [back to overview]Cmax Assessment After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng/mL)
NCT00292942 (8) [back to overview]Number of Participants With AEs Occurring in Greater Frequency in the 2.0 mg/kg IV AS Group Then in the Placebo Group to Access Safety and Tolerability of AS
NCT00292942 (8) [back to overview]Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng*hr/mL)
NCT00292942 (8) [back to overview]Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng/mL)
NCT00292942 (8) [back to overview]Range of Pharmacokinetic Parameters for Dihydroartemisinin (DHA) After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng*hr/mL)
NCT00292942 (8) [back to overview]Tmax Assessment After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (hr)
NCT00297882 (2) [back to overview]Cure Rate Day 14
NCT00297882 (2) [back to overview]Cure Rate on Day 28
NCT00298610 (7) [back to overview]Safety - Severity of Adverse Events
NCT00298610 (7) [back to overview]Safety - Serious Adverse Event (SAE) Relationship to Study Drug
NCT00298610 (7) [back to overview]Percentage of Parasite Clearance
NCT00298610 (7) [back to overview]Number of Subjects With Fever Clearance
NCT00298610 (7) [back to overview]Change in Percentage of Parasites Detected at 48 Hours
NCT00298610 (7) [back to overview]Safety - Adverse Events Relationship to Study Drug
NCT00298610 (7) [back to overview]Safety - Severity of Serious Adverse Events (SAE's)
NCT00331136 (8) [back to overview]Percentage of Patients With Fever Clearance at Day 1, 2 and 3
NCT00331136 (8) [back to overview]Number of Subjects With P. Falciparum Gametocytes During the Trial
NCT00331136 (8) [back to overview]Crude ACPR on Day 14, 28 and 42
NCT00331136 (8) [back to overview]Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
NCT00331136 (8) [back to overview]Parasite Clearance Time
NCT00331136 (8) [back to overview]Fever Clearance Time
NCT00331136 (8) [back to overview]Number of Patients With PCR-corrected ACPR on Day 14
NCT00331136 (8) [back to overview]Number of Patients With PCR-corrected ACPR on Day 42
NCT00379821 (38) [back to overview]Number of Clinical Malaria Episodes Per Year of Follow-up
NCT00379821 (38) [back to overview]Number of Participants Infected With Parasites With the Mutation Pfcrt 76T at Recrudescent Episodes of Malaria
NCT00379821 (38) [back to overview]Number of Participants Infected With Parasites With the Mutation Pfcrt 76T on Day 0 of the Initial Episode of Malaria
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Pharmacokinetics of Chloroquine Represented by Maximum Concentration (Cmax)
NCT00379821 (38) [back to overview]Number of Participants With New and Recrudescent Infections After Subsequent New Episodes
NCT00379821 (38) [back to overview]Number of Participants With New and Recrudescent Malaria Infections After Initial Treatment
NCT00379821 (38) [back to overview]Pharmacokinetics of Chloroquine Represented by Time of Maximal Concentration (Tmax) and Chloroquine Half-life
NCT00379821 (38) [back to overview]Time to First Malaria Episode in Participants Who Travelled and Slept Outside the City Versus Those Who Did Not Travel and Sleep Outside the City.
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]"Number of Participants in Each Treatment Arm Who Change From Normal to Abnormal on Any Questions of the Neurological Examination"
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants 3 Years of Age or Younger.
NCT00379821 (38) [back to overview]Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants Greater Than 3 Years to 5 Years of Age.
NCT00379821 (38) [back to overview]Nearest Neighbor Index as a Measure of Spatial Pattern of the Distribution of Malaria Cases in Ndirande
NCT00379821 (38) [back to overview]Number of Cases of Severe Malaria in Each Treatment Arm
NCT00403260 (8) [back to overview]Fever Clearance Time
NCT00403260 (8) [back to overview]Parasite Clearance Time
NCT00403260 (8) [back to overview]PCR-corrected ACPR on Day 14
NCT00403260 (8) [back to overview]Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
NCT00403260 (8) [back to overview]Adverse Events and Clinically Significant Laboratory Results
NCT00403260 (8) [back to overview]Crude ACPR on Days 14 and 28
NCT00403260 (8) [back to overview]Fever Clearance at Day 1, 2 and 3
NCT00403260 (8) [back to overview]Parasite Clearance at Day 1, 2 and 3
NCT00422084 (8) [back to overview]Parasite Clearance Time
NCT00422084 (8) [back to overview]PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14
NCT00422084 (8) [back to overview]PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28
NCT00422084 (8) [back to overview]Adverse Events and Clinically Significant Laboratory Results
NCT00422084 (8) [back to overview]Fever Clearance Time
NCT00422084 (8) [back to overview]Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28
NCT00422084 (8) [back to overview]Percentage of Patients With Fever Clearance at Day 1, 2 and 3
NCT00422084 (8) [back to overview]Proportion of Patients With Parasite Clearance at Day 1, 2 and 3
NCT00440999 (9) [back to overview]Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3
NCT00440999 (9) [back to overview]Number of Participants With Adverse Events
NCT00440999 (9) [back to overview]Percentage of Subjects With PCR-corrected Cure Rate on Days 14, 21, and 28
NCT00440999 (9) [back to overview]Fever Clearance Time
NCT00440999 (9) [back to overview]Parasite Clearance Time
NCT00440999 (9) [back to overview]Crude Cure Rate on Day 14
NCT00440999 (9) [back to overview]Crude Cure Rate on Days 21 and 28.
NCT00440999 (9) [back to overview]Percentage of Subjects With Crude and PCR-corrected Cure Rate on Day 42
NCT00440999 (9) [back to overview]Percentage of Subjects With Fever Clearance on Days 1, 2, and 3
NCT00444106 (4) [back to overview]Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)
NCT00444106 (4) [back to overview]Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42
NCT00444106 (4) [back to overview]Relationship Between Changes in Auditory Function and Treatment Groups
NCT00444106 (4) [back to overview]Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)
NCT00541385 (8) [back to overview]Fever Clearance Time
NCT00541385 (8) [back to overview]Number of Subjects With ≥1 Adverse Event
NCT00541385 (8) [back to overview]Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28
NCT00541385 (8) [back to overview]Percentage of Participants With PCR-Corrected ACPR on Day 28
NCT00541385 (8) [back to overview]Percentage of Participants With PCR-Corrected ACPR on Day 14
NCT00541385 (8) [back to overview]Parasite Clearance Time
NCT00541385 (8) [back to overview]Proportion of Subjects With Fever Cleared on Days 1, 2, and 3
NCT00541385 (8) [back to overview]Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3
NCT00682630 (5) [back to overview]Artesunate (AS) and Dihydroartemisinin (DHA) Pharmacokinetics: Tmax, Half-life
NCT00682630 (5) [back to overview]Artesunate (AS) and Dihydroartemisinin (DHA): AUC0-last, AUC0-∞
NCT00682630 (5) [back to overview]Pyronaridine (PP), Artesunate (AS), Dihydroartemisinin (DHA) Pharmacokinetics: Cmax
NCT00682630 (5) [back to overview]Pyronaridine Pharmacokinetics: AUC0-last, AUC0-∞
NCT00682630 (5) [back to overview]Pyronaridine Pharmacokinetics: Tmax, Half-life
NCT01156389 (4) [back to overview]Summary of Treatment Emergent Adverse Events
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: Half-life, Tmax
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: Cmax
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: AUC0-tau, AUC0-∞
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Cmax
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: t1/2
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Tmax
NCT01523002 (6) [back to overview]Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞
NCT01523002 (6) [back to overview]World Health Organization (WHO) Treatment Emergent Adverse Events
NCT01523002 (6) [back to overview]Non-WHO Listed Treatment Emergent Adverse Events
NCT01594931 (7) [back to overview]Parasite Clearance
NCT01594931 (7) [back to overview]Fever Clearance
NCT01594931 (7) [back to overview]PCR-Corrected ACPR at Day 28
NCT01594931 (7) [back to overview]PCR-Corrected ACPR at Day 14
NCT01594931 (7) [back to overview]Parasite Clearance Time
NCT01594931 (7) [back to overview]Fever Clearance Time
NCT01594931 (7) [back to overview]Adverse Events (AEs)
NCT01868438 (3) [back to overview]Area Under the Concentration-time Curve From Hour 0 to the Last Sampling Point (AUC 0-t) for Pyronaridine and Dihydroartemisinin (DHA)
NCT01868438 (3) [back to overview]Safety Evaluation - Summary of Adverse Events
NCT01868438 (3) [back to overview]Tmax and Terminal Half Life for Pyronaridine, Artesunate and DHA
NCT01955382 (2) [back to overview]Safety
NCT01955382 (2) [back to overview]Parasite Clearance Half-life
NCT02354534 (3) [back to overview]Number of Participants With Serious Adverse Events
NCT02354534 (3) [back to overview]Histologic Regression of CIN2/3
NCT02354534 (3) [back to overview]Viral Clearance of HPV
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 42
NCT04368910 (8) [back to overview]Fever Clearance Time (FCT)
NCT04368910 (8) [back to overview]Number of Participants With Adverse Events (AEs)
NCT04368910 (8) [back to overview]Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3
NCT04368910 (8) [back to overview]Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 28
NCT04368910 (8) [back to overview]Parasite Clearance Time (PCT)
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 14
NCT04374019 (12) [back to overview]Heart Function
NCT04374019 (12) [back to overview]Mortality
NCT04374019 (12) [back to overview]Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale
NCT04374019 (12) [back to overview]Number of Patients That Required Hospitalization
NCT04374019 (12) [back to overview]Rate of Organ Failure
NCT04374019 (12) [back to overview]Progression to ICU Care or Ventilation
NCT04374019 (12) [back to overview]Number of Patients Who Required Vasopressors
NCT04374019 (12) [back to overview]Number of Patients Who Required ICU Services
NCT04374019 (12) [back to overview]Number of Patients That Required Oxygen Supplementation
NCT04374019 (12) [back to overview]Number of Patients That Required Mechanical Ventilation
NCT04374019 (12) [back to overview]Rate of Severe Adverse Events
NCT04374019 (12) [back to overview]Clinical Deterioration

Cardiovascular Responses: Number of Participants With Changes in Blood Pressure and Heart Rate After Infusion

Cardiovascular Responses: Number of participants with changes in blood pressure and heart rate after infusion to determine change from baseline (NCT00292942)
Timeframe: screening, on Day -1, on Days 1, 2, and 3, and at each follow-up visit

InterventionParticipants (Count of Participants)
Systolic BP change of at least 20mmHg72445700Systolic BP change of at least 20mmHg72445701Systolic BP change of at least 20mmHg72445702Systolic BP change of at least 20mmHg72445703Heart Rate change of at least 15bpm72445701Heart Rate change of at least 15bpm72445702Heart Rate change of at least 15bpm72445703Heart Rate change of at least 15bpm72445700
IncreaseDecreaseNo significant change
Placebo1
2 mg/kg Intravenous Artesunate1
8 mg/kg Intravenous Artesunate1
Placebo5
2 mg/kg Intravenous Artesunate5
8 mg/kg Intravenous Artesunate6
Placebo4
2 mg/kg Intravenous Artesunate4
4 mg/kg Intravenous Artesunate6
8 mg/kg Intravenous Artesunate3
Placebo0
2 mg/kg Intravenous Artesunate0
4 mg/kg Intravenous Artesunate0
8 mg/kg Intravenous Artesunate0
Placebo2
2 mg/kg Intravenous Artesunate2
4 mg/kg Intravenous Artesunate1
8 mg/kg Intravenous Artesunate4

[back to top]

Number of Participants With AEs

The general strategy of the safety analysis was to examine the clinical tolerability and laboratory safety parameter data and determine if there were any trends amongst the dose levels concerning all AEs and drug related AEs. (NCT00292942)
Timeframe: up to 21 days

InterventionParticipants (Count of Participants)
All AEs72445700All AEs72445701All AEs72445702All AEs72445703Drug Related AEs72445700Drug Related AEs72445701Drug Related AEs72445702Drug Related AEs72445703
No AEsSubjects with 1 AESubjects with 2 AEsSubjects with ≥3 AEs
Placebo0
2 mg/kg Intravenous Artesunate0
8 mg/kg Intravenous Artesunate0
Placebo3
2 mg/kg Intravenous Artesunate3
4 mg/kg Intravenous Artesunate0
4 mg/kg Intravenous Artesunate1
4 mg/kg Intravenous Artesunate4
8 mg/kg Intravenous Artesunate3
Placebo2
4 mg/kg Intravenous Artesunate2
8 mg/kg Intravenous Artesunate1
8 mg/kg Intravenous Artesunate2
2 mg/kg Intravenous Artesunate1
2 mg/kg Intravenous Artesunate2
4 mg/kg Intravenous Artesunate3

[back to top]

Cmax Assessment After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng/mL)

Cmax was calculated after single 2.0, 4.0 and 8.0 mg/kg dose of Artesunate daily for 3 days (ng/mL) (NCT00292942)
Timeframe: Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion

,,
Interventionng/mL (Mean)
Cmax 1Cmax 2Cmax 3
2 mg/kg Intravenous Artesunate173517102358
4 mg/kg Intravenous Artesunate301529232933
8 mg/kg Intravenous Artesunate605759435762

[back to top]

Number of Participants With AEs Occurring in Greater Frequency in the 2.0 mg/kg IV AS Group Then in the Placebo Group to Access Safety and Tolerability of AS

Comparison of number of participants with AEs reported for the placebo control and those treated with the 2.0 mg/kg of IV AS to access safety and tolerability (NCT00292942)
Timeframe: up to 21 days

,
InterventionParticipants (Count of Participants)
DysguesiaDizzinessHeadacheParethesiaParosmiaErythemaPruritus GeneralizedTendernessVenipuncture Site InflammationEye PainBack PainMuscle Strain
2 mg/kg Intravenous Artesunate413111111111
Placebo101000000000

[back to top]

Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng*hr/mL)

For artesunic acid, AUC0-last was determine for each dose; as well as the total area under the curve (AUClastTOTAL), calculated as the sum of AUClast for each of the doses (ng*hr/mL) (NCT00292942)
Timeframe: Pre-dose, 5, 20, 40 minutes after infusion and 1, 2, 4, 8, 24 and 72 hours after infusion

,,
Interventionng*hr/mL (Mean)
AUC24 1 (ng.hr/mL)AUC24 2 (ng.hr/mL)AUC24 3 (ng.hr/mL)AUC last 1 (ng.hr/mL)AUC last 2 (ng.hr/mL)AUC last 3 (ng.hr/mL)AUC last TOTAL (ng.hr/mL)
2 mg/kg Intravenous Artesunate136897893511629329333027
4 mg/kg Intravenous Artesunate2325174618802421163616275683
8 mg/kg Intravenous Artesunate57665272437946315728437414733

[back to top]

Range of Pharmacokinetic Parameters for Artesunic Acid After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng/mL)

For the predicted concentration at the time of dose administration (C0) was determine for each dose (ng/mL) (NCT00292942)
Timeframe: Pre-dose, 5, 20, 40 minutes after infusion and 1, 2, 4, 8, 24 and 72 hours after infusion

,,
Interventionng/mL (Mean)
C0 1C0 2C0 3
2 mg/kg Intravenous Artesunate148401199210408
4 mg/kg Intravenous Artesunate290561726523417
8 mg/kg Intravenous Artesunate535036638054674

[back to top]

Range of Pharmacokinetic Parameters for Dihydroartemisinin (DHA) After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (ng*hr/mL)

For DHA, AUC24, and AUClast were calculated for each dose, as well as the total area under the curve extrapolated to infinite time (AUC∞TOTAL), calculated as the sum of AUC24 for each dose +C24/λz. (NCT00292942)
Timeframe: Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion

,,
Interventionng*hr/mL (Mean)
AUC24 1AUC24 2AUC24 3AUC last 1AUC last 2AUC last 3AUC oo TOTAL
2 mg/kg Intravenous Artesunate1982186522041954184721716051
4 mg/kg Intravenous Artesunate41223509374840653394370111379
8 mg/kg Intravenous Artesunate89928122857188428011840525685

[back to top]

Tmax Assessment After Single 2.0, 4.0 and 8.0 mg/kg Dose of Artesunate Daily for 3 Days (hr)

Tmax was calculated after single 2.0, 4.0 and 8.0 mg/kg dose of Artesunate daily for 3 days (hr) (NCT00292942)
Timeframe: Pre-dose, 5, 20, 40 minutes after infution and 1, 2, 4, 8, 24 and 72 hours after infusion

,,
Interventionhr (Mean)
Tmax 1 (hr)Tmax 2 (hr)Tmax 3 (hr)
2 mg/kg Intravenous Artesunate0.2440.1670.122
4 mg/kg Intravenous Artesunate0.2080.2080.292
8 mg/kg Intravenous Artesunate0.2080.1810.250

[back to top]

Cure Rate Day 14

To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment (NCT00297882)
Timeframe: Day 0-14

InterventionParticipants (Count of Participants)
1 Artemether-Lumefantrine192
2 Amodiaquine-Artesunate563

[back to top]

Cure Rate on Day 28

To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua (NCT00297882)
Timeframe: Day 0 - 28

InterventionParticipants (Count of Participants)
1 Artemether-Lumefantrine AL197
2 Amodiaquine-Artesunate AQ-AS603

[back to top]

Safety - Severity of Adverse Events

Determine the safety (defined as severity of AE's using the Common Toxicity Criteria) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of adverse events (Number)
MildModerateSevere
Artesunate and Malarone123176

[back to top]

Safety - Serious Adverse Event (SAE) Relationship to Study Drug

Determine the safety (defined as relationship to study drug of SAE's) (NCT00298610)
Timeframe: Up to 14 days

InterventionNumber of events (Number)
None or RemotePossible, Probable, Definate
Artesunate and Malarone01

[back to top]

Percentage of Parasite Clearance

The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears (NCT00298610)
Timeframe: 24 and 48 hours post dose

Interventionpercentage of parasite clearance (Mean)
24 hours post dose48 hours post dose
Artesunate and Malarone99.42199.998

[back to top]

Number of Subjects With Fever Clearance

Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (<37.5C) sustained for 24 hours (NCT00298610)
Timeframe: Within 48 hours post dose

InterventionParticipants (Count of Participants)
Artesunate and Malarone29

[back to top]

Change in Percentage of Parasites Detected at 48 Hours

Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases (NCT00298610)
Timeframe: 48 hours

Interventionpercentage of parasite change (Mean)
Artesunate and Malarone99.998

[back to top]

Safety - Adverse Events Relationship to Study Drug

Determine the safety (defined as relationship to study drug of AE's and SAE's) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of adverse events (Number)
None or remotePossible, probable, definate
Artesunate and Malarone8957

[back to top]

Safety - Severity of Serious Adverse Events (SAE's)

Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of events (Number)
MildModerateSevere
Artesunate and Malarone001

[back to top]

Percentage of Patients With Fever Clearance at Day 1, 2 and 3

"Patient without fever for 2 consecutive readings taken between 8 and 24 hours apart.~NB: Percentage of fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment. Since only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful." (NCT00331136)
Timeframe: Days 1, 2, 3

,,,
InterventionParticipants (Count of Participants)
Clearance by >0 - 24 hoursClearance by >24 - 48 hoursClearance by >48 - 72 hoursNo clearance achieved
Group A (Tablets)3000
Group B (Tablets)5000
Group C (Tablets)3000
Group D (Granules)1000

[back to top]

Number of Subjects With P. Falciparum Gametocytes During the Trial

"The number of gametocytes per μl at Days 0, 3, 7, 14, 21, 28, 35, and 42 summarised from blood slides taken on the respective days.~P. falciparum gametocytes are responsible for transmission from host to vector." (NCT00331136)
Timeframe: Day 42

,,,
InterventionParticipants (Count of Participants)
Baseline>0-24 hours>24-48 hours>48-72 hours>72 hours - Day 7>Day 7 - Day 28>Day 28 - Day 42>Day 42
Group A (Tablets)23222100
Group B (Tablets)01010000
Group C (Tablets)11001000
Group D (Granules)11000000

[back to top]

Crude ACPR on Day 14, 28 and 42

The proportion of patients with crude (non-PCR corrected) ACPR. (NCT00331136)
Timeframe: Days 14, 28, 42

,,,
InterventionParticipants (Count of Participants)
Day 14Day 28Day 42
Group A (Tablets)11117
Group B (Tablets)13106
Group C (Tablets)151513
Group D (Granules)141412

[back to top]

Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 28 days, without previously meeting any of the criteria for early treatment failure, late clinical failure, or late parasitological failure. (NCT00331136)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Group A (Tablets)11
Group B (Tablets)13
Group C (Tablets)15
Group D (Granules)14

[back to top]

Parasite Clearance Time

The time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings taken between 8 and 24 hours apart. (NCT00331136)
Timeframe: Day 3

Interventionhours (Median)
Group A (Tablets)16.4
Group B (Tablets)16.1
Group C (Tablets)8.1
Group D (Granules)8.3

[back to top]

Fever Clearance Time

"The time from first dosing to the first normal reading with fever clearance, defined as 2 consecutive assessments without fever (<37.5°C) taken between 8 and 24 hours apart.~NB: Time to fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment. Since only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful." (NCT00331136)
Timeframe: Day 3

Interventionhours (Median)
Group A (Tablets)8.2
Group B (Tablets)8.6
Group C (Tablets)8.2
Group D (Granules)8.2

[back to top]

Number of Patients With PCR-corrected ACPR on Day 14

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 14 days. (NCT00331136)
Timeframe: Day 14

InterventionParticipants (Count of Participants)
Group A (Tablets)11
Group B (Tablets)13
Group C (Tablets)15
Group D (Granules)14

[back to top]

Number of Patients With PCR-corrected ACPR on Day 42

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 42 days. (NCT00331136)
Timeframe: Day 42

InterventionParticipants (Count of Participants)
Group A (Tablets)10
Group B (Tablets)8
Group C (Tablets)15
Group D (Granules)13

[back to top]

Number of Clinical Malaria Episodes Per Year of Follow-up

Clinical malaria episode was defined as at least one symptom of malaria and a positive malaria smear. The number of clinical malaria episodes (not including the initial malaria episode) reported by participants during follow up is presented as the number per Person Years at Risk (PYAR). (NCT00379821)
Timeframe: 1 year

InterventionEpisodes per PYAR (Number)
Chloroquine Plus Artesunate0.61
Chloroquine Plus Atovaquone-Proguanil0.68
CQ Plus Azithromycin0.64
CQ Monotherapy0.59

[back to top]

Number of Participants Infected With Parasites With the Mutation Pfcrt 76T at Recrudescent Episodes of Malaria

Participants were enrolled in the study at the time of the initial episode of malaria. If the participant presented with a subsequent episode of malaria at any time during the one year of follow-up, the presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing. (NCT00379821)
Timeframe: Recrudescent episodes of malaria within one year of enrollment

Interventionparticipants (Number)
Chloroquine Plus Artesunate0
Chloroquine Plus Atovaquone-Proguanil0
CQ Plus Azithromycin1
CQ Monotherapy0

[back to top]

Number of Participants Infected With Parasites With the Mutation Pfcrt 76T on Day 0 of the Initial Episode of Malaria

The presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing. (NCT00379821)
Timeframe: Day 0 of initial episode of malaria

Interventionparticipants (Number)
Chloroquine Plus Artesunate1
Chloroquine Plus Atovaquone-Proguanil0
CQ Plus Azithromycin0
CQ Monotherapy0

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of first subsequent malaria episode (Episode 1)

InterventionParticipants (Number)
Chloroquine Plus Artesunate46
Chloroquine Plus Atovaquone-Proguanil42
CQ Plus Azithromycin37
CQ Monotherapy39

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of initial malaria episode (Episode 0)

InterventionParticipants (Number)
Chloroquine Plus Artesunate143
Chloroquine Plus Atovaquone-Proguanil133
CQ Plus Azithromycin137
CQ Monotherapy135

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of second subsequent malaria episode (Episode 2)

InterventionParticipants (Number)
Chloroquine Plus Artesunate17
Chloroquine Plus Atovaquone-Proguanil14
CQ Plus Azithromycin12
CQ Monotherapy6

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of third subsequent malaria episode (Episode 3)

InterventionParticipants (Number)
Chloroquine Plus Artesunate4
Chloroquine Plus Atovaquone-Proguanil4
CQ Plus Azithromycin6
CQ Monotherapy0

[back to top]

Pharmacokinetics of Chloroquine Represented by Maximum Concentration (Cmax)

1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s. Compartmental population pharmacokinetic modeling was used due to highly sparse data. The model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL/F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd/F), and the inter-compartmental clearance for chloroquine (Q/F). Only these primary population pharmacokinetic parameters could be estimated using the type of data collected. The best-fit population PK model was then used to estimate individual parameter estimates to derive Cmax in nanograms per milliliter (ng/mL). (NCT00379821)
Timeframe: Day 0 - Day 28

Interventionng/mL chloroquine (Median)
Chloroquine Plus Artesunate351.0
Chloroquine Plus Atovaquone-Proguanil345.1
CQ Plus Azithromycin353.1
CQ Monotherapy384.2

[back to top]

Number of Participants With New and Recrudescent Infections After Subsequent New Episodes

Participants were enrolled at the time of initial malaria episode and treated. Subsequent to treatment, participants who subsequently suffered new malaria episodes were monitored for the additional occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation. (NCT00379821)
Timeframe: Day 28 to 1 year

,,,
Interventionparticipants (Number)
New infectionsRecrudescent infections
Chloroquine Plus Artesunate00
Chloroquine Plus Atovaquone-Proguanil00
CQ Monotherapy11
CQ Plus Azithromycin12

[back to top]

Number of Participants With New and Recrudescent Malaria Infections After Initial Treatment

Participants were enrolled at the time of initial malaria episode and treated. Subsequent to treatment, subjects were monitored for the occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation. (NCT00379821)
Timeframe: 28 days to 1 year

,,,
Interventionparticipants (Number)
New infectionsRecrudescent infections
Chloroquine Plus Artesunate01
Chloroquine Plus Atovaquone-Proguanil00
CQ Monotherapy00
CQ Plus Azithromycin10

[back to top]

Pharmacokinetics of Chloroquine Represented by Time of Maximal Concentration (Tmax) and Chloroquine Half-life

1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s. Compartmental population pharmacokinetic modeling was used due to highly sparse data. The model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL/F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd/F), and the inter-compartmental clearance for chloroquine (Q/F). Only these primary population pharmacokinetic parameters could be estimated using the type of data collected. The best-fit population PK model was then used to estimate individual parameter estimates to derive Tmax and half-life. (NCT00379821)
Timeframe: Day 0 - Day 28

,,,
InterventionHours (Median)
Time of maximal concentration (Tmax)Chloroquine half-life
Chloroquine Plus Artesunate5.641.6
Chloroquine Plus Atovaquone-Proguanil5.646.2
CQ Monotherapy5.644.5
CQ Plus Azithromycin5.541.3

[back to top]

Time to First Malaria Episode in Participants Who Travelled and Slept Outside the City Versus Those Who Did Not Travel and Sleep Outside the City.

The cumulative hazard of having a malaria attack within one year for those participants who travelled and slept in rural areas (outside the city) versus those who did not was calculated and is presented as a life table to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point. Participants are right-censored at the time of first malaria episode. Participants who did not develop malaria during follow-up or were lost to follow-up were censored at the time of their last visit. (NCT00379821)
Timeframe: Days 0 - 420

,
Interventionparticipants (Number)
Days 0-27 - Number At RiskDays 0-27 - Number with MalariaDays 0-27 - Number CensoredDays 28-55 - Number At RiskDays 28-55 - Number with MalariaDays 28-55 - Number CensoredDays 56-83 - Number At RiskDays 56-83 - Number with MalariaDays 56-83 - Number CensoredDays 84-111 - Number At RiskDays 84-111 - Number with MalariaDays 84-111 - Number CensoredDays 112-139 - Number At RiskDays 112-139 - Number with MalariaDays 112-139 - Number CensoredDays 140-167 - Number At RiskDays 140-167 - Number with MalariaDays 140-167 - Number CensoredDays 168-195 - Number At RiskDays 168-195 - Number with MalariaDays 168-195 - Number CensoredDays 196-223 - Number At RiskDays 196-223 - Number with MalariaDays 196-223 - Number CensoredDays 224-251 - Number At RiskDays 224-251 - Number with MalariaDays 224-251 - Number CensoredDays 252-279 - Number At RiskDays 252-279 - Number with MalariaDays 252-279 - Number CensoredDays 280-307 - Number At RiskDays 280-307 - Number with MalariaDays 280-307 - Number CensoredDays 308-335 - Number At RiskDays 308-335 - Number with MalariaDays 308-335 - Number CensoredDays 336-363 - Number At RiskDays 336-363 - Number with MalariaDays 336-363 - Number CensoredDays 364-391 - Number At RiskDays 364-391 - Number with MalariaDays 364-391 - Number CensoredDays 392 - 420 - Number At RiskDays 392 - 420 - Number with MalariaDays 392 - 420 - Number Censored
Participants Who Did Not Travel and Sleep Outside the City20102817341015991613412101124510327941390497716701564435752503740038202
Participants Who Traveled and Slept Outside the City43206336913263301121298121627013172403222153161964161761241601281407412988113821032100101

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of fourth subsequent malaria episode (Episode 4)

InterventionParticipants (Number)
Chloroquine Plus Atovaquone-Proguanil2
CQ Plus Azithromycin1

[back to top]

"Number of Participants in Each Treatment Arm Who Change From Normal to Abnormal on Any Questions of the Neurological Examination"

"A basic age-appropriate neurological examination was conducted on Day 28 of each malaria illness episode and also at Days 112 and 224, and at 1 year. Subjects were were counted as a change from 'normal' to 'abnormal' if they had the 'normal' (or not-applicable) response for the initial day 28 exam and an 'abnormal' response at their last exam. If a subject did not have an exam at 1 year then the last available exam that was not associated with an illness episode (either Day 112 or 224) was used." (NCT00379821)
Timeframe: 1 Year

InterventionParticipants (Number)
Chloroquine Plus Artesunate6
Chloroquine Plus Atovaquone-Proguanil4
CQ Plus Azithromycin3
CQ Monotherapy12

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of first subsequent malaria episode (Episode 1)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate24.2
Chloroquine Plus Atovaquone-Proguanil21.7
CQ Plus Azithromycin22.4
CQ Monotherapy25.3

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of fourth subsequent malaria episode (Episode 4)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil27.3
CQ Plus Azithromycin24.9

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of initial malaria episode (Episode 0)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate27.2
Chloroquine Plus Atovaquone-Proguanil32.1
CQ Plus Azithromycin27.5
CQ Monotherapy26.2

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of second subsequent malaria episode (Episode 2)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate26.1
Chloroquine Plus Atovaquone-Proguanil23.0
CQ Plus Azithromycin23.3
CQ Monotherapy23.5

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of third subsequent malaria episode (Episode 3)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate26.4
Chloroquine Plus Atovaquone-Proguanil20.7
CQ Plus Azithromycin18.6
CQ Monotherapy16.2

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of first subsequent malaria episode (Episode 1)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate14.5
Chloroquine Plus Atovaquone-Proguanil14.2
CQ Plus Azithromycin18.3
CQ Monotherapy17.2

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of fourth subsequent malaria episode (Episode 4)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil13.9

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of initial malaria episode (Episode 0)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate14.3
Chloroquine Plus Atovaquone-Proguanil16.2
CQ Plus Azithromycin17.8
CQ Monotherapy15.5

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of second subsequent malaria episode (Episode 2)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate116
Chloroquine Plus Atovaquone-Proguanil14.7
CQ Plus Azithromycin17.3
CQ Monotherapy16.3

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of third subsequent malaria episode (Episode 3)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate17.8
Chloroquine Plus Atovaquone-Proguanil13.6
CQ Plus Azithromycin15.3
CQ Monotherapy14.3

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of first subsequent malaria episode (Episode 1)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate43.9
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin43.7
CQ Monotherapy43.6

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of fourth subsequent malaria episode (Episode 4)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of initial malaria episode (Episode 0)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.3

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of second subsequent malaria episode (Episode 2)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy46.4

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of third subsequent malaria episode (Episode 3)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of first subsequent malaria episode (Episode 1)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of fourth subsequent malaria episode (Episode 4)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of initial malaria episode (Episode 0)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of second subsequent malaria episode (Episode 2)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of third subsequent malaria episode (Episode 3)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants 3 Years of Age or Younger.

Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment. Group means are stratified by participants 3 years of age and under, and over 3 to 5 years of age. (NCT00379821)
Timeframe: 1 year

InterventionGrams/Deciliter (Mean)
Chloroquine Plus Artesunate11.6
Chloroquine Plus Atovaquone-Proguanil11.7
CQ Plus Azithromycin12.2
CQ Monotherapy11.8

[back to top]

Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants Greater Than 3 Years to 5 Years of Age.

Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment. Group means are stratified by participants 3 years of age and under, and over 3 to 5 years of age. (NCT00379821)
Timeframe: 1 year

InterventionGrams/Deciliter (Mean)
Chloroquine Plus Artesunate12.5
Chloroquine Plus Atovaquone-Proguanil12.3
CQ Plus Azithromycin12.1
CQ Monotherapy12.5

[back to top]

Nearest Neighbor Index as a Measure of Spatial Pattern of the Distribution of Malaria Cases in Ndirande

The Global Positioning System (GPS) was used to establish the coordinates of participants' homes. The distribution of these coordinates was analyzed for evidence of clustering, or occurring closer together than would be expected on the basis of chance. Nearest Neighbor Index is a ratio of the observed mean distance over the expected mean distance. If the index is less than 1, the pattern exhibits clustering. If the index is greater than 1, the trend is toward dispersion. (NCT00379821)
Timeframe: 1 year

InterventionIndex (Number)
All Groups0.328

[back to top]

Number of Cases of Severe Malaria in Each Treatment Arm

A case of severe malaria included one or more of the following: Hemoglobin ≤5 g/dL; prostration; respiratory distress; bleeding; recent seizures, coma or obtundation (Blantyre coma score < 5); inability to drink, or persistent vomiting. All cases were then adjudicated by a panel of investigators prior to analysis. (NCT00379821)
Timeframe: 1 Year

InterventionCases of severe malaria (Number)
Chloroquine Plus Artesunate0
Chloroquine Plus Atovaquone-Proguanil2
CQ Plus Azithromycin2
CQ Monotherapy6

[back to top]

Fever Clearance Time

Fever clearance time was defined as the time from first dosing to first normal reading of temperature (<37.5°C taken axillary or tympanic; <38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.

Interventionhours (Median)
Pyronaridine - Artesunate15.9
Mefloquine Plus Artesunate16.0

[back to top]

Parasite Clearance Time

Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).

Interventionhours (Median)
Pyronaridine - Artesunate31.7
Mefloquine Plus Artesunate32.0

[back to top]

PCR-corrected ACPR on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Day 14

Interventionpercentage of subjects (Mean)
Pyronaridine - Artesunate99.9
Mefloquine Plus Artesunate99.5

[back to top]

Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00403260)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
Pyronaridine - Artesunate99.2
Mefloquine Plus Artesunate98.1

[back to top]

Adverse Events and Clinically Significant Laboratory Results

Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities (NCT00403260)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life threatenining AENr subj. with ≥1 AE leading to deathNr subj with ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Mefloquine Plus Artesunate190943223044
Pyronaridine - Artesunate3891536024055

[back to top]

Crude ACPR on Days 14 and 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Days 14 and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) on Day 14Cure rate (%) on Day 28
Mefloquine Plus Artesunate99.596.7
Pyronaridine - Artesunate99.998.7

[back to top]

Fever Clearance at Day 1, 2 and 3

Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (<37.5°C axillary/tympanic or <38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Mefloquine Plus Artesunate78.996.298.4
Pyronaridine - Artesunate78.595.999.2

[back to top]

Parasite Clearance at Day 1, 2 and 3

Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (48h after first dose)
Mefloquine Plus Artesunate31.679.890.5
Pyronaridine - Artesunate38.583.891.5

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned)

Interventionhours (Median)
PA Group23.9
AL Group24.0

[back to top]

PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
PA Group99.9
AL Group100

[back to top]

PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
PA Group99.5
AL Group99.2

[back to top]

Adverse Events and Clinically Significant Laboratory Results

Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities. (NCT00422084)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr pat with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
AL Group241123205056
PA Group509275301001619

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT00422084)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated

Interventionhours (Median)
PA Group7.9
AL Group8.0

[back to top]

Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 14 and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) at Day 14Cure rate (%) at Day 28
AL Group10097.2
PA Group10098.9

[back to top]

Percentage of Patients With Fever Clearance at Day 1, 2 and 3

Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 1, 2, 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
AL Group87.098.799.3
PA Group88.799.099.5

[back to top]

Proportion of Patients With Parasite Clearance at Day 1, 2 and 3

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 1, 2, 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
AL Group52.897.299.7
PA Group68.198.199.5

[back to top]

Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3

Percentage of subjects with parasite clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine30.688.096.7
Pyronaridine Artesunate71.699.5100.0

[back to top]

Number of Participants With Adverse Events

Number of participants with adverse events, including clinically significant laboratory results, ECG, vital signs or physical examination abnormalities. (NCT00440999)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to study drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Chloroquine7223002022
Pyronaridine Artesunate9227200000

[back to top]

Percentage of Subjects With PCR-corrected Cure Rate on Days 14, 21, and 28

Cure on Days 14, 21, and 28 is defined as the absence of P. vivax parasitaemia on Days 14, 21, and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14, 21, and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) at Day 14Cure rate (%) at Day 21Cure rate (%) at Day 28
Chloroquine99.599.597.9
Pyronaridine Artesunate100.0100.098.1

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature (<37.5°C for axillary/tympanic or <38°C for oral/rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Interventionhours (Median)
Pyronaridine Artesunate15.8
Chloroquine23.8

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Interventionhours (Median)
Pyronaridine Artesunate23.1
Chloroquine32.0

[back to top]

Crude Cure Rate on Day 14

Cure rate on Day 14 is defined as the absence of P. vivax parasitaemia on Day 14 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14

,
InterventionParticipants (Count of Participants)
Total curedCambodiaIndiaIndonesia/MaumereThailand/Mae SotThailand/Mae Ramatbaseline P. vivax = 250-5,000/uLbaseline P. vivax = >5,000/uL-10,000/uLbaseline P. vivax = >10,000/uLage ≤ 12 yearsage ≥ 12 yearsGender - MaleGender - FemalePrevious P. vivax episode in the past = noPrevious P. vivax episode in the past = yes
Chloroquine2097333104647805970111981486193116
Pyronaridine Artesunate21775331149506958891320416453107110

[back to top]

Crude Cure Rate on Days 21 and 28.

Cure on Day 21 and 28 is defined as the absence of P. vivax parasitaemia on Day 21 and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 21 and 28

,
Interventionpercentage of cured subjects (Number)
Cure rate (%) at Day 21Cure rate (%) at Day 28
Chloroquine99.598.0
Pyronaridine Artesunate99.597.1

[back to top]

Percentage of Subjects With Crude and PCR-corrected Cure Rate on Day 42

Cure on Day 42 is defined as the absence of P. vivax parasitaemia on Day 42 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 42

,
Interventionpercentage of subjects (Number)
Crude cure rate (%)PCR-corrected cure rate (%)
Chloroquine92.194.1
Pyronaridine Artesunate95.595.0

[back to top]

Percentage of Subjects With Fever Clearance on Days 1, 2, and 3

Percentage of subjects with fever clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Day 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine58.488.397.4
Pyronaridine Artesunate78.689.997.0

[back to top]

Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)

Audiometric measurements such as pure-tone threshold (air conduction tested at 250 to 8000 HZ) day 3, 7, 28 and 42 following initiation of treatment, including changes from baseline. Pure-tone average (PTA) calculated for each ear by averaging the pure-tone threshold values at 500, 1000, 2000 and 3000 HZ. (NCT00444106)
Timeframe: Baseline (Day 1), 3, 7, 28 and Day 42

,,
InterventiondB (Mean)
Baseline Right EarChange from baseline to Day 3 Right EarChange from baseline to Day 7 Right EarChange from baseline to Day 28 Right EarChange from baseline to Day 42 Right EarBaseline Left EarChange from baseline to Day 3 Left EarChange from baseline to Day 7 Left EarChange from baseline to Day 28 Left EarChange from baseline to Day 42 Left Ear
Artemether-lumefantrine12.2-2.5-2.2-2.7-3.011.4-1.2-1.7-2.0-1.5
Artesunate-mefloquine12.7-1.9-2.6-3.6-3.112.5-1.2-1.4-2.5-3.0
Atovaquone-proguanil (Malarone)12.0-2.4-2.6-2.6-3.311.3-1.5-1.3-1.8-2.1

[back to top]

Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42

Percentage of patients with clearance of asexual parasitemia (observed by optical microscopy) within 7 days of initiation of trial treatment without recrudescence within 14, 28 and 42 days respectively after initiation of treatment. Patients with recurrent parasitemia and paired PCR results were classified as either a new infection (different paired genotypes) or a recrudescence (matching paired genotypes). Patients without paired PCR results or ambiguous results were classified as treatment failures. (NCT00444106)
Timeframe: Days 14, 28 and 42

,,
InterventionPercentage of Participants (Number)
Day 14Day 28Day 42
Artemether-lumefantrine (Coartem)99.498.797.5
Artesunate-mefloquine98.198.198.1
Atovaquone-proguanil (Malarone)100.098.198.1

[back to top]

Relationship Between Changes in Auditory Function and Treatment Groups

ABR Wave III latency (ms) changes from baseline to Day 7 in the three drug exposure groups. (NCT00444106)
Timeframe: From Baseline to Day 7

,,
Interventionms (Mean)
Baseline Right EarChange from baseline to Day 7 Right EarBaseline Left EarChange from baseline to Day 7 Left Ear
Artemether-lumefantrine (Coartem)3.860.013.850.01
Artesunate-mefloquine3.86-0.043.82-0.03
Atovaquone-proguanil (Malarone)3.89-0.013.88-0.01

[back to top]

Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)

"To demonstrate the safety of artemether-lumefantrine after 3 days of treatment in patients with acute, uncomplicated falciparum malaria by testing the null hypothesis that the rate of auditory abnormalities is ≥ 15% in the population treated with artemether-lumefantrine as assessed by ABR at Day 7 following initiation of treatment compared with their baseline values. An auditory nerve abnormality is here defined as a greater than 0.30 ms change in Wave III latency from baseline to Day 7. Exact Pearson-Clopper two-sided 95% confidence limits were constructed for all three treatment groups." (NCT00444106)
Timeframe: 7 days

InterventionPercentage of Participants (Number)
Artemether-lumefantrine (Coartem)2.6

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00541385)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated (within the 42-day study period)

Interventionhours (Median)
PA Group8.1
AL Group8.1

[back to top]

Number of Subjects With ≥1 Adverse Event

(NCT00541385)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
AL Group14380002033
PA Group285132102066

[back to top]

Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 14 and 28, without correction by PCR. Crude ACPR on Day 14 and 28 is defined as the absence of parasitaemia on Day 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Days 14 and 28

,
Interventionpercentage of subjects (Number)
Percentage of Participants with ACPR at Day 14Percentage of Participants with ACPR at Day 28
AL Group10089.2
PA Group10090.2

[back to top]

Percentage of Participants With PCR-Corrected ACPR on Day 28

Percentage of patients with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28. The PCR-corrected ACPR on Day 28 is defined as the absence of parasitaemia on Day 28 without the patient's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Day 28

Interventionpercentage of cured subjects (Number)
PA Group97.6
AL Group98.8

[back to top]

Percentage of Participants With PCR-Corrected ACPR on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14. The PCR-corrected ACPR on Day 14 is defined as the absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
PA Group100.0
AL Group100.0

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 or on any other day if the subject spontaneously returned within the 42-day study period

Interventionhours (Median)
PA Group24.1
AL Group24.2

[back to top]

Proportion of Subjects With Fever Cleared on Days 1, 2, and 3

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Percentage of Participants with fever clearance at Day 1 (24h after first dose)Percentage of Participants with fever clearance at Day 2 (48h after first dose)Percentage of Participants with fever clearance at Day 3 (48h after first dose)
AL Group81.096.898.4
PA Group87.198.599.6

[back to top]

Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Percentage of Participants with parasite clearance at Day 1 (24h after first dose)Percentage of Participants with parasite clearance at Day 2 (48h after first dose)Percentage of Participants with parasite clearance at Day 3 (72h after first dose)
AL Group43.795.298.8
PA Group49.995.597.0

[back to top]

Artesunate (AS) and Dihydroartemisinin (DHA) Pharmacokinetics: Tmax, Half-life

Tmax: time to maximum concentration Half-life: computed as ln (2)/kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionhours (Mean)
AS TmaxDHA TmaxAS half-lifeDHA half-life
Clinical Trial Reference Tablets0.4881.140.5491.53
To-Be-Marketed Tablets0.5481.390.5381.84

[back to top]

Artesunate (AS) and Dihydroartemisinin (DHA): AUC0-last, AUC0-∞

AUC0-last: Area under the concentration-time curve from time 0 (0 h) through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn AUC0-∞: Area under the concentration-time curve from time 0 (0 h) to infinity, computed using the linear trapezoidal rule as AUClast + CLQCT / Kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionng*hr/ml (Mean)
AS AUC0-lastDHA AUC0-lastAS AUC0-∞DHA AUC0-∞9
Clinical Trial Reference Tablets13921501552166
To-Be-Marketed Tablets12121201372143

[back to top]

Pyronaridine (PP), Artesunate (AS), Dihydroartemisinin (DHA) Pharmacokinetics: Cmax

Cmax: maximum peak observed concentration (NCT00682630)
Timeframe: PP sampling performed at predose at at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period AS, DHA sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionng/ml (Mean)
PP CmaxAS CmaxDHA Cmax
Clinical Trial Reference Tablets512183987
To-Be-Marketed Tablets533154959

[back to top]

Pyronaridine Pharmacokinetics: AUC0-last, AUC0-∞

AUC0-last: Area under the concentration-time curve from time 0 (0 h) through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn AUC0-∞: Area under the concentration-time curve from time 0 (0 h) to infinity, computed using the linear trapezoidal rule as AUClast + CLQCT / Kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period

,
Interventionng*day/ml (Mean)
AUC0-lastAUC0-∞
Clinical Trial Reference Tablets729877
To-Be-Marketed Tablets762904

[back to top]

Pyronaridine Pharmacokinetics: Tmax, Half-life

Tmax: time to maximum concentration Half-life: computed as ln (2)/kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period

,
Interventiondays (Mean)
TmaxHalf-life
Clinical Trial Reference Tablets0.18414.2
To-Be-Marketed Tablets0.16614.1

[back to top]

Summary of Treatment Emergent Adverse Events

Including all the treatment emergent adverse events, the number of subjects discontinued due to adverse events and the number of subjects with serious adverse events. (NCT01156389)
Timeframe: Throughout the study

,
InterventionParticipants (Count of Participants)
Mild treatment emergent adverse eventsModerate treatment emergent adverse eventsSevere treatment emergent adverse eventsSubjects discontinued due to adverse eventsSubjects with serious adverse events
Arm A Ritonavir Plus Pyramax126040
Arm B Pyramax153010

[back to top]

Pharmacokinetics Analysis: Half-life, Tmax

"Half-life and Tmax for pyronaridine, artesunate, DHA:~Tmax - time of the maximum observed concentration Half life - apparent plasma terminal elimination half-life, computed as ln (2)/Kel~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionhours (Mean)
Pyronaridine half- life (adjusted to a common dose of 9.72 mg/kg)Pyronaridine Tmax (adjusted to a common dose of 9.72 mg/kg)Artesunate half-life (adjusted to common dose of 3.25 mg/kg)Artesunate Tmax (adjusted to common dose of 3.25 mg/kg)DHA half-life (adjusted for common 3.25 mg/kg artesunate dose)DHA Tmax (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax3842.320.4251.222.271.90
Arm B Pyramax321.61.440.4650.842.351.44

[back to top]

Pharmacokinetics Analysis: Cmax

"Cmax for pyronaridine, artesunate, DHA:~Cmax - maximum peak observed concentration~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionng/ml (Mean)
Pyronaridine Cmax (adjusted to a common dose of 9.72 mg/kg)Artesunate Cmax (adjusted to common dose of 3.25 mg/kg)DHA Cmax (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax480.2128.2611.4
Arm B Pyramax407.5108.7779.2

[back to top]

Pharmacokinetics Analysis: AUC0-tau, AUC0-∞

"AUC0-tau, AUC0-∞ for pyronaridine, artesunate, DHA:~AUC0-tau - area under the concentration-time curve from Hour 0 to the scheduled time of the next dose AUC0-∞ - area under the concentration-time curve from Hour 0 through the last quantifiable concentration time~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionhours*ng/ml (Mean)
Pyronaridine AUC0-tau (adjusted to a common dose of 9.72 mg/kg)Pyronaridine AUC0-∞ (adjusted to a common dose of 9.72 mg/kg)Artesunate AUC0-tau (adjusted to common dose of 3.25 mg/kg)Artesunate AUC0-∞(adjusted to common dose of 3.25 mg/kg)DHA AUC0-tau (adjusted for common 3.25 mg/kg artesunate dose)DHA AUC0-∞ (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax2291244185.4185.413081310
Arm B Pyramax222131815014919781982

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Cmax

"Cmax of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: Cmax = maximum peak observed concentration" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Geometric Mean)
Period 1 Cmax MetoprololPeriod 2 Cmax MetoprololPeriod 1 Cmax α-hydroxymetoprololPeriod 2 Cmax α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing152.7228.673.966.8

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: t1/2

"t1/2 of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: t1/2 = apparent terminal phase half-life" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Geometric Mean)
Period 1 t1/2 MetoprololPeriod 2 t1/2 MetoprololPeriod 1 t1/2 α-hydroxymetoprololPeriod 2 t1/2 α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing3.393.287.347.55

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Tmax

"tmax of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: tmax = time to maximum observed concentration." (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Median)
Period 1 tmax MetoprololPeriod 2 tmax MetoprololPeriod 1 tmax α-hydroxymetoprololPeriod 2 tmax α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing1.51.001.51.5

[back to top]

Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞

"AUC0-t & AUC0-∞ of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: AUC = area under the concentration-time curve; AUC0-t = AUC from Hour 0 to the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn; AUC0-∞ = AUC from Hour 0 to infinity" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionng.h/ml (Geometric Mean)
Period 1 AUC0-t MetoprololPeriod 1 AUC0-∞ MetoprololPeriod 2 AUC0-t MetoprololPeriod 2 AUC0-∞ MetoprololPeriod 1 AUC0-t α-hydroxymetoprololPeriod 1 AUC0-∞ α-hydroxymetoprololPeriod 2 AUC0-t α-hydroxymetoprololPeriod 2 AUC0-∞ α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing685746895958707804601739

[back to top]

World Health Organization (WHO) Treatment Emergent Adverse Events

To assess the safety of redosing a 3-day regimen of pyronaridine-artesunate. Grade 1: mild adverse event Grade 2: moderate adverse event Grade 3: severe and undesirable adverse event Grade 4: life threatening adverse event Grade 5: fatal adverse event resulting in death (NCT01523002)
Timeframe: 140 days

,
Interventionparticipants (Number)
Grade 1 toxicityGrade 2 toxicityGrade 3 toxicityGrade 4 toxicity
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing251220
Arm B: Pyronaridine-artesunate 60-day Redosing241742

[back to top]

Non-WHO Listed Treatment Emergent Adverse Events

To assess the safety of redosing a 3-day regimen of pyronaridine-artesunate (NCT01523002)
Timeframe: 140 days

,
Interventionparticipants (Number)
MildModerateSevereLife-threatening
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing23500
Arm B: Pyronaridine-artesunate 60-day Redosing211400

[back to top]

Parasite Clearance

Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide. The proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3. (NCT01594931)
Timeframe: Days 1, 2, and 3

,,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)749396
Group B: Pyronaridine/Artesunate (9:3 mg/kg)829698
Group C: Pyronaridine/Artesunate (12:4 mg/kg)849599

[back to top]

Fever Clearance

Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours. The proportion of subjects with fever clearance was summarized at Days 1, 2, and 3. (NCT01594931)
Timeframe: Days 1, 2 and 3

,,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)969999
Group B: Pyronaridine/Artesunate (9:3 mg/kg)919696
Group C: Pyronaridine/Artesunate (12:4 mg/kg)96100100

[back to top]

PCR-Corrected ACPR at Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT01594931)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)95
Group B: Pyronaridine/Artesunate (9:3 mg/kg)99
Group C: Pyronaridine/Artesunate (12:4 mg/kg)99

[back to top]

PCR-Corrected ACPR at Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT01594931)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)100
Group B: Pyronaridine/Artesunate (9:3 mg/kg)100
Group C: Pyronaridine/Artesunate (12:4 mg/kg)100

[back to top]

Parasite Clearance Time

Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide (NCT01594931)
Timeframe: Thick blood slides were examined every 8 hours until at least 72 hours or until a negative smear was recorded

Interventionhours (Mean)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)36.9
Group B: Pyronaridine/Artesunate (9:3 mg/kg)33.6
Group C: Pyronaridine/Artesunate (12:4 mg/kg)30.8

[back to top]

Fever Clearance Time

Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (<37.5°C)). The method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject. Any subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading >37.5°C during the 24 hours after initial dosing, were not included in this end point analysis. (NCT01594931)
Timeframe: Every 8 hours for at least 72 hours after the first dose

Interventionhours (Mean)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)16.8
Group B: Pyronaridine/Artesunate (9:3 mg/kg)24.0
Group C: Pyronaridine/Artesunate (12:4 mg/kg)17.0

[back to top]

Adverse Events (AEs)

An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study (NCT01594931)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 AE leading to deathNr subj. with ≥1 AE leading to study withdrawal
Group A: Pyronaridine/Artesunate (6:2 mg/kg)106353003
Group B: Pyronaridine/Artesunate (9:3 mg/kg)90330001
Group C: Pyronaridine/Artesunate (12:4 mg/kg)91361101

[back to top]

Area Under the Concentration-time Curve From Hour 0 to the Last Sampling Point (AUC 0-t) for Pyronaridine and Dihydroartemisinin (DHA)

Pharmacokinetic blood sampling for first or second intervention dose (NCT01868438)
Timeframe: First intervention: Day 1 pre-dose to Day 43 visit (D1, 2, 3, 4, 6, 8, 15, 22, 29, 36, 43) ; second intervention: Day 61 pre-dose to Day 103 visit (D61, 62, 63, 64, 66, 68, 75, 82, 89, 96, 103)

,
Interventionng*h/ml (Mean)
AUC 0-t pyronaridineAUC 0-t DHA
Total Receiving Pyronaridine-artesunate Granules11324829
Total Receiving Pyronaridine-artesunate Tablets116401119

[back to top]

Safety Evaluation - Summary of Adverse Events

(NCT01868438)
Timeframe: End of study (Day 103)

,
InterventionParticipants (Count of Participants)
Adverse event before treatmentTreatment-emergent adverse eventTreatment-related adverse eventSerious adverse eventSerious adverse drug reactionAdverse event leading to discontinuation
Total Receiving Pyronaridine-artesunate Granules02314003
Total Receiving Pyronaridine-artesunate Tablets22214003

[back to top]

Tmax and Terminal Half Life for Pyronaridine, Artesunate and DHA

Pharmacokinetic blood sampling for first or second intervention dose (NCT01868438)
Timeframe: First intervention: Day 1 pre-dose to Day 43 visit (D1, 2, 3, 4, 6, 8, 15, 22, 29, 36, 43) ; second intervention: Day 61 pre-dose to Day 103 visit (D61, 62, 63, 64, 66, 68, 75, 82, 89, 96, 103)

,
Interventionhours (Mean)
Tmax pyronaridineHalf-life pyronaridineTmax artesunateHalf-life artesunateTmax DHAHalf-life DHA
Total Receiving Pyronaridine-artesunate Granules1.7591.81.520.712.261.43
Total Receiving Pyronaridine-artesunate Tablets2.16390.980.331.461.50

[back to top]

Safety

To assess the safety of adjunct treatment with oAC; specifically, children were hospitalized while their vital signs were measured, IV site inspected, state of consciousness assessed, and selected symptoms (nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and dizziness) surveyed at 0, 2, 4, 6, 8, and 12 hours, and then every 6 hours until 48 hours or until parasitemia became undetectable (one negative thick blood film), whichever was later. (NCT01955382)
Timeframe: During patient treatment up to 48 hours

InterventionParticipants (Count of Participants)
AS + oAC35
AS Only (Water)35

[back to top]

Parasite Clearance Half-life

To compare parasite clearance half-life in patients treated with IV AS + oAC or IV AS alone; parasite clearance half-life is the time it takes for the parasite density to decrease by half, and can be assessed by analysing frequent parasite density counts at 0, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, and 48 hours after initiating treatment. (NCT01955382)
Timeframe: During patient treatment

InterventionHours (Mean)
AS + oAC1.733
AS Only (Water)1.973

[back to top]

Number of Participants With Serious Adverse Events

Number of participants with serious adverse events or dose limiting toxicities related to the study intervention assessed using Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. (NCT02354534)
Timeframe: 41 weeks

InterventionParticipants (Count of Participants)
50 mg Artesunate Suppositories, 1 Cycle0
200 mg Artesunate Suppositories, 1 Cycle0
200 mg Artesunate Suppositories,2 Cycles0
200 mg Artesunate Suppositories,3 Cycles0

[back to top]

Histologic Regression of CIN2/3

Number of participants who had histologic regression from cervical intraepithelial neoplasia (CIN) 2/3 to CIN 1 or less, as assessed by colposcopically-directed biopsies. Histologic regression is defined as disappearance of the high grade lesion (CIN2/3) without surgical intervention. (NCT02354534)
Timeframe: 41 weeks

InterventionParticipants (Count of Participants)
50 mg Artesunate Suppositories, 1 Cycle2
200 mg Artesunate Suppositories, 1 Cycle7
200 mg Artesunate Suppositories,2 Cycles5
200 mg Artesunate Suppositories,3 Cycles5

[back to top]

Viral Clearance of HPV

Number of participants whose human papillomavirus (HPV) genotypes present at study entry become undetectable without surgical intervention. HPV genotyping detects strains of HPV present at each timepoint. For this outcome, we evaluated whether strains of HPV detected at study entry became undetectable during the study participation. (NCT02354534)
Timeframe: 41 weeks

InterventionParticipants (Count of Participants)
50 mg Artesunate Suppositories, 1 Cycle1
200 mg Artesunate Suppositories, 1 Cycle3
200 mg Artesunate Suppositories,2 Cycles4
200 mg Artesunate Suppositories,3 Cycles1

[back to top]

Crude Cure Rate on Day 42

Proportion of subjects with crude cure rate at Day 42, defined as absence of parasitaemia on Day 42, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 42

Interventionpercentage of subjects (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Fever Clearance Time (FCT)

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT04368910)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit (Days 7, 14, 28 and 42)

Interventionhours (Median)
Pyronaridine - Artesunate16.0
Chloroquine31.9

[back to top]

Number of Participants With Adverse Events (AEs)

Number of Participants with AEs, including clinically significant laboratory results, electrocardiogram (ECG), vital signs or physical examination abnormalities (NCT04368910)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. with≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Chloroquine109002000
Pyronaridine - Artesunate107000000

[back to top]

Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3

Fever clearance is defined as at least 2 consecutive normal body temperature measurements (<37.5 C axillary/tympanic or <38.0 C oral/rectal) obtained within an interval of 7 to 25 hours postdosing (NCT04368910)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of participants (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine41.791.7100.0
Pyronaridine - Artesunate76.992.3100.0

[back to top]

Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3

Parasite clearance is defined as at least 2 consecutive negative smears for asexual parasites obtained within an interval of 7 to 25 hours post-dosing (NCT04368910)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of participants (Number)
Day 1 (24h after first dose)Day 2 (48h after first dose)Day 3 (72h after first dose)
Chloroquine0.026.760.0
Pyronaridine - Artesunate30.892.3100.0

[back to top]

Crude Cure Rate on Day 28

Percentage of subjects with crude cure rate at Day 28, defined as absence of parasitaemia on Day 28, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 28

Interventionpercentage of participants (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Parasite Clearance Time (PCT)

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT04368910)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned within the 42-day period)

Interventionhours (Median)
Pyronaridine - Artesunate32.0
Chloroquine63.9

[back to top]

Crude Cure Rate on Day 14

Percentage of subjects with crude cure rate at Day 14, defined as absence of parasitaemia on Day 14, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 14

Interventionpercentage of participants (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Heart Function

Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms. (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C1
Arm D0

[back to top]

Mortality

Percentage of patients who have died by day 14. (NCT04374019)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale

"Number of participants who died or had greater than a 2-point decrease in COVID 7-Point Ordinal Outcomes Scale from Day to Day 14.~COVID 7-point ordinal outcomes scale:~Death~Hospitalized on invasive mechanical ventilation or ECMO~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04374019)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Number of Patients That Required Hospitalization

Number of patients that required hospitalization during study treatment (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C4
Arm D4

[back to top]

Rate of Organ Failure

Number of patients that experienced severe respiratory or other organ failure. (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Progression to ICU Care or Ventilation

Percentage of patients requiring ICU admission or ventilation. (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Number of Patients Who Required Vasopressors

Number of patients who required vasopressor treatment Days 1 to 28 (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Number of Patients Who Required ICU Services

Number of patients who required ICU services during study treatment Days 1-28. (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Number of Patients That Required Oxygen Supplementation

Number of patients that required oxygen supplementation during study treatment Days 1-28 (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A1
Arm B1
Arm C1
Arm D1

[back to top]

Number of Patients That Required Mechanical Ventilation

Number of patients that required mechanical ventilation during the study period. Days 1-28 (NCT04374019)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]

Rate of Severe Adverse Events

Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events. (NCT04374019)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Arm A1
Arm B0
Arm C1
Arm D0

[back to top]

Clinical Deterioration

Number of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes. (NCT04374019)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Arm A0
Arm B0
Arm C0
Arm D0

[back to top]